前往化源商城

93-15-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_AG_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as agonists of the human M1 muscarinic receptor (CHRM1; M1). In this assay, CHO-K1 cells stably expressing human M1 are loaded, intracellularly with the calcium indicator dye, Fluo-8, followed by treatment with agonist control or test compounds. As designed, compounds that act as CHRM1 agonists will increase intracellular calcium mobilization, resulting in increased relative fluorescence of the indicator dye and well fluorescence. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were dispensed to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices). Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read.
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

%_Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for the entire run, i.e. any compound that exhibited greater % activation than the entire screen's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-1, and for inactive compounds 1-0.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250 mM (pH 8.0); (Sigma P8761)
Agonist: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1019440
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 6
First Page: 2327
Last Page: 2335
DOI: 10.1016/j.bmc.2009.02.009
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
35IC50=35000nM
34.4IC50=34400nM
35.7IC50=35700nM
38.7IC50=38700nM
43IC50=43000nM
145IC50=145000nMOutside typical range
56.2IC50=56200nM
32IC50=32000nM
3.8IC50=3800nM
1.9IC50=1900nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_PAM_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as positive allosteric modulators (PAMs) and increase activity of the human M1 muscarinic receptor (CHRM1; M1) in cells pre-treated with a known agonist. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye, followed by addition of test compounds and subsequent treatment with the activator acetylcholine at a concentration that results in 20% activation (EC20). As designed, compounds that act as CHRM1 PAMs will increase calcium mobilization, resulting in increased intracellular calcium and relative fluorescence of the indicator dye beyond that of the EC20 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 micromolar.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 degrees C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 micrograms/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 microliters of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 degrees C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 microliters of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 degrees C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC20 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and;
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

% Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Acetylcholine at EC20 and DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter on an individual plate basis, i.e. any compound that exhibited greater % activation than the plate based cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The inactive compounds of this assay have an activity score range of 0 to 78 and the active compounds have an activity score range of 50 to 100.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50?g/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.74
9.74
9.74
9.74
9.74
9.74
9.74
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-antagonist-CTF
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive SPA70 (final concentration range of 2.8 nM to 92uM for the antagonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of RIF (final concentration of 2uM) in the antagonist mode, using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent antagonists are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Inhibitor10.153140.755621Partial curve; partial efficacy-4.99340.40.7519-22.755618-2.20 0 0 0 0 0 0 0 0 0 0 0-18.96314.228615.423221.78321.990312.7098.251211.76180.02953.02123.5483.2806-18.963QC'd by NCI-NPB
Inhibitor70.794641.186310Single point of activity-4.153.06540.7616-40.68630.5-30 0 0 0 0 0 0 0 0 0 0 0-30.5719-5.82211.70573.85692.3906-3.0434-5.1259-0.0204-4.50967.67922.2068-0.8314-30.5719QC'd by SigmaAldrich
Inhibitor20.258137.67710Partial curve; partial efficacy; poor fit-4.69340.60.8367-32.1775.5-2.40 0 0 0 0 0 0 0 0 0 0 0-23.48087.31197.43618.07377.8115-1.654-1.67136.0557-3.6601-2.9743-2.3177-14.0308-23.4808QC'd by NCI-NPB
Inhibitor16.091637.601210Partial curve; partial efficacy; poor fit-4.79341.13410.8452-30.60127-2.40 0 0 0 0 0 0 0 0 0 0 0-24.2519.691212.09586.967813.07042.3816-4.34997.21867.4852.3057-3.9474-15.5947-24.251QC'd by NCI-NPB
Inactive0-5.54.95490.59534.5-6.942940 0 0 0 0 0 0 0 0 0 0 05.5505-12.581-3.6735-0.3298-5.7361-15.7857-1.8915-7.6677-3.58716.49081.87073.07685.5505QC'd by NIEHS
Inactive0-5.34.95490.51875.50.001740 0 0 0 0 0 0 0 0 0 0 03.4570.4546-1.44463.17460.2283-1.07621.529-0.8791-2.08193.819910.29192.23513.457QC'd by Labotest
Inactive000414.77677.975815.1119.93217.842411.36965.53624.83674.11242.91079.735117.294514.7767QC'd by Microsource
Inactive00047.48485.14659.28654.05173.33396.02881.82297.78417.71411.52646.27186.01687.4848QC'd by SigmaAldrich
Inactive0-4.44.95490.4225-2.299911.540 0 0 0 0 0 0 0 0 0 0 0-0.249911.032112.73438.29587.7656.439510.40716.53437.858915.144413.27616.7991-0.2499QC'd by FLUKA
Inactive00044.71299.82915.22989.11547.79320.69023.11126.00811.17723.21623.76586.64644.7129QC'd by Timtec
Inactive0-5.21.34430.52729-4.545640 0 0 0 0 0 0 0 0 0 0 08.55970.32651.3817-2.9939-6.7498-13.3714-9.4912-0.51632.79663.1192-0.47189.56148.5597QC'd by ASDI
Inactive0004-3.5795-4.3598-0.5776-3.2591-6.8076-5.0883-8.613-3.3668-6.4244-6.5159-4.2276-4.6923-3.5795QC'd by SigmaAldrich
Inactive0004-13.4251-8.7965-1.2528-9.2469-7.9021-3.3764-1.4523-13.4156-8.74672.7588-1.4294-13.8991-13.4251QC'd by Enamine
Inactive0004-9.8167-11.8528-7.2424-12.0513-7.4969-8.9732-12.2154-12.0728-9.5269-6.1546-3.8393-4.0575-9.8167QC'd by Enamine
Inactive0-51.92820.56798-1.469940 0 0 0 0 0 0 0 0 0 0 06.0779-0.0024-0.20133.1935-0.4054-9.5582-2.4938-2.18322.51884.45953.186311.92486.0779QC'd by Enamine
Inactive0-5.354.95490.76345.5-5.365240 0 0 0 0 0 0 0 0 0 0 06.0484-8.1291-5.3769-2.77281.7572-8.221-7.0739-5.55873.9782.57455.20226.39186.0484QC'd by SIGMA
Inactive0-4.451.10.5944321.51440 0 0 0 0 0 0 0 0 0 0 19.85350.7672-4.57174.81875.40172.6732-2.94765.81258.301312.52973.147124.82849.8535QC'd by SIGMA
Inactive0-5.350.60.65698.5-6.764740 0 0 0 0 0 0 0 0 0 0 04.5331-5.4295-8.5539-2.72830.1802-7.8806-0.2857-2.14165.38450.02812.39559.85114.5331QC'd by LightBiologicals
Inactive0004-5.3594-8.871-12.8425-6.6113-4.5224-10.2103-10.3208-6.0527-14.4677-12.9358-16.9058-11.3122-5.3594QC'd by SIGMA
Inactive0-4.351.13410.555112-1.306940 0 0 0 0 0 0 0 0 0 0 08.9371-6.0891-1.9072-0.54095.0417-4.9288-1.0154-0.45852.45211.48640.16.07468.9371QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-antagonist-ONEGlo
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive SPA70 (final concentration range of 2.8 nM to 92uM for the antagonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of RIF (final concentration of 2uM) in the antagonist mode, using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent antagonists are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Inhibitor0.064134.705122Complete curve; partial efficacy-7.19340.80.8198-15.205119.5-1.20 0 0 0 0 0 0 0 0 0 0 0-18.427412.341830.693411.06878.702711.1596-4.0097-0.7424-17.7591-18.9041-6.35-11.9997-18.4274QC'd by NCI-NPB
Inhibitor0.057143.182922Complete curve; partial efficacy-7.24340.30.8029-17.182926-1.20 0 0 0 0 0 0 0 0 0 0 11.79619.343712.079420.15979.87981.19632.351-1.4583-2.3569-9.52431.5791-17.65241.796QC'd by NCI-NPB
Inhibitor1044.889521Partial curve; partial efficacy-50.50.7545-32.389512.5-2.20 0 0 0 0 0 0 0 0 0 0 0-24.45936.37118.740215.923510.6417-2.33847.0423-0.518-9.6117-3.1015-13.119-5.0111-24.4593QC'd by Specs
Inhibitor25.1189202.453110Single point of activity-4.64.95490.8549-206.4531-4-30 0 0 0 0 0 0 0 0 1 0 0-157.118-4.9883-9.5737-8.2214-6.9034-18.4403-0.8015-24.8599-8.40283.7254107.134129.6841-157.118QC'd by Analyticon
Inhibitor5.011944.96610Partial curve; partial efficacy; poor fit-5.30.40.7248-41.4663.5-2.40 0 0 0 0 0 0 0 0 0 0 0-23.2895.976-6.5685-4.0459-5.1171-3.6133-8.2625-11.6513-11.3707-17.7211-9.4112-34.555-23.289QC'd by Analyticon
Inhibitor10Single point of activity00-3-31.2598-4.64091.1143-7.1165-26.93820.15-13.91455.77672.71096.231732.3237-10.1053-31.2598QC'd by SIGMA
Inhibitor57.095176.982710Single point of activity-4.24344.95490.8136-167.97549.0073-30 0 0 1 0 0 0 1 0 0 0 0-125.3564-2.5428-0.74036.0074-119.4048-11.1656-3.8852-1.9563-143.01776.318137.620550.1208-125.3564QC'd by NCI-NPB
Inhibitor28.615381.180810Partial curve; partial efficacy; poor fit-4.54342.72020.7315-71.96919.2117-2.40 0 0 0 0 0 0 0 1 0 0 0-65.0709-9.34540.0654-8.67176.944226.239712.80327.63739.597675.75736.8623-21.7124-65.0709QC'd by NCI-NPB
Inhibitor28.6153146.918310Single point of activity-4.54344.95490.9263-140.53826.3801-30 0 0 0 0 0 0 0 0 1 1 0-138.6637-0.54878.3171-2.0665.2057-1.8734-6.119911.73982.179639.669148.4234165.9679-138.6637QC'd by NCI-NPB
Inhibitor10Single point of activity00-3-30.74153.15832.3786-4.6143-4.83942.05472.0009-1.0351-6.02710.6182-19.358410.4489-30.7415QC'd by Analyticon
Inhibitor6.309658.840410Partial curve; partial efficacy; poor fit-5.20.60.417-65.9909-7.1505-2.40 0 0 0 0 0 0 0 0 0 0 1-28.9537-10.278-7.0923-12.3469-20.4971-17.6764-24.1328-4.8477-2.6254-57.8867-28.7749-43.6104-28.9537QC'd by Adooq
Inhibitor7.943335.709610Partial curve; partial efficacy; poor fit-5.11.62660.6292-32.20963.5-2.40 0 0 0 0 0 0 1 0 0 0 0-31.2215-8.6776-0.010226.2164.2017-7.6517-3.874711.94249.9824-11.8036-23.4099-21.0046-31.2215QC'd by MedChem Express
Inhibitor3548.1339245.146910Single point of activity-2.454.95490.8456-238.64696.5-30 0 0 0 0 0 0 0 0 0 0 0-189.2328-10.2316-11.668-5.7125-6.9939-6.83584.6961-0.7482-3.938510.139967.82411.1988-189.2328QC'd by SIGMA
Inhibitor3548.133962.154810Single point of activity-2.454.0950.6256-60.15482-30 0 0 0 0 0 0 0 0 0 0 0-44.97659.0235-3.711.40378.8489-20.5128-6.788510.687512.245816.8535-8.1934-5.3762-44.9765QC'd by Spectrum Chemical
Inhibitor3548.1339224.207110Single point of activity-2.454.95490.908-226.7071-2.5-30 0 0 0 0 0 0 0 0 0 0 0-188.92260.6552-3.0475-20.07884.3432-7.7208-4.391-10.9476-14.7305-15.72889.415518.4273-188.9226QC'd by Spectrum Chemical
Inactive0004-11.6855-10.3618-6.7493-13.8491-4.0803-8.693.1376-3.5124-6.64858.867923.3566-19.7661-11.6855QC'd by NIEHS
Inactive0-4.454.95490.59135.6731-7.278340 0 0 0 0 0 0 0 0 0 0 027.36422.8347-4.98130.3609-23.9819-6.2913-0.0932-3.8252-15.0975-15.0152-1.0423-10.058427.3642QC'd by NIEHS
Inactive0-5.251.3310.8583-16.27280.540 0 0 0 0 0 0 0 0 0 0 0-15.2273-2.78552.24051.2511-0.30423.2449-5.3421-1.1406-2.134-11.0911-10.1778-14.1452-15.2273QC'd by Microsource
Inactive0-74.95490.4875-12.02527.540 0 0 0 0 0 0 0 0 0 0 0-17.94165.45699.45630.9594-16.173-11.6471-23.6404-23.7713.0401-13.6573-3.3944-2.453-17.9416QC'd by SigmaAldrich
Inactive0-5.22.40640.526320.5918-9.057440 0 0 0 0 0 0 0 0 1 0 1-20.2572.5975-10.44924.0575-21.7145-4.1317-16.8048-9.6264-16.01219.3402-20.985518.4895-20.257QC'd by FLUKA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-agonist-ONEGlo
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9uM), positive control rifampicin (RIF; final concentration range of 2.8 nM to 92uM for the agonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92uM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1uL of the media in the agonist mode using a BioRAPTR FRD and incubated for 24 h at 37C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent agonists are ranked higher than compounds that showed apparent antagonists.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Activator14.3416104.68542Partial curve; high efficacy-4.843410.9919101.0889-3.59612.10 0 0 0 0 0 0 0 0 0 0 083.8217-5.0801-3.2987-3.4347-0.032-0.5082-3.4679-4.9059-2.01116.607233.435158.618783.8217QC'd by NCI-NPB
Activator25.5034117.202841Partial curve; high efficacy-4.59341.55790.972117.76270.55992.10 0 0 0 0 0 0 0 0 0 0 0103.3007-1.2511-2.7602-6.6167-0.0605-5.67752.2614-0.14648.643812.86419.114350.0412103.3007QC'd by NCI-NPB
Activator31.6228123.593440Partial curve; high efficacy-4.54.95490.9863122.5186-1.07482.10 0 0 0 0 0 0 0 0 0 0 0106.3529-1.8934-3.4581-3.7753-0.6018-3.758-4.229-0.9602-3.3997.09925.555816.7238106.3529QC'd by Analyticon
Activator28.183895.483440Partial curve; partial efficacy-4.551.96730.983596.32520.84182.20 0 0 0 0 0 0 0 0 0 0 072.9863-0.90180.35540.70880.1280.3466-1.38184.17771.71428.226217.96232.910672.9863QC'd by MedChem Express
Activator31.6228133.31840Partial curve; high efficacy-4.51.92820.9932132.865-0.4532.10 0 0 0 0 0 0 0 0 0 0 1-26.5067-1.345-2.46089.2529-0.3764-2.2195-0.666.200620.341762.313997.1543124.4054-26.5067QC'd by USP
Activator1.139282.369826Complete curve; partial efficacy-5.94344.95490.980679.5801-2.78971.20 0 0 0 0 0 0 0 0 0 0 1-8.8595-6.0747-3.93610.8373-3.8801-4.3545-1.7272-0.513610.874178.708390.844968.7426-8.8595QC'd by NCI-NPB
Activator2.27349.889423Complete curve; partial efficacy-5.64341.24750.958544.0109-5.87851.20 0 0 0 0 0 0 0 0 0 0 035.6087-4.4347-7.1334-8.2321-4.2161-5.6276-4.0085-4.3417.381919.996732.016651.531635.6087QC'd by NCI-NPB
Activator4.535247.623422Complete curve; partial efficacy-5.343410.97538.4365-9.18691.20 0 0 0 0 0 0 0 0 0 0 032.3303-6.888-9.4868-10.9846-13.4891-7.3468-8.7296-2.7383-1.26776.575419.047135.092932.3303QC'd by NCI-NPB
Activator16.091648.572421Partial curve; partial efficacy-4.79341.62590.96747.6766-0.89582.20 0 0 0 0 0 0 0 0 0 0 043.41312.86553.37681.2511-0.5359-5.7465-5.372-1.002-0.61711.29410.870830.007143.4131QC'd by NCI-NPB
Activator7.079533.998521Complete curve; partial efficacy-5.151.62660.860433.027-0.97141.20 0 0 0 0 0 0 0 0 0 0 036.6967-1.92390.55984.07911.538-1.549-1.5547-4.55952.667717.157325.347717.240236.6967QC'd by Microsource
Activator14.125445.012521Complete curve; partial efficacy-4.852.33320.950549.01133.99891.20 0 0 0 0 0 0 0 0 0 0 043.90152.575410.42212.13222.62136.6166-9.0E-46.93954.058112.340318.178742.030143.9015QC'd by MedChem Express
Activator11.220240.232521Partial curve; partial efficacy-4.951.41630.934335-5.23252.20 0 0 0 0 0 0 0 0 0 0 033.2046-4.1192-4.572-4.0695-3.3798-5.8283-3.6991-3.6725-6.44379.890318.689517.954533.2046QC'd by Analyticon
Activator14.125458.328721Complete curve; partial efficacy-4.852.53340.979458.89750.56881.20 0 0 0 0 0 0 0 0 0 0 054.63993.51161.77872.62132.4685-2.9488-3.0533-4.10945.3066.893821.233747.459654.6399QC'd by Bio Vision
Activator1040.410521Complete curve; partial efficacy-51.92820.993234.9051-5.50541.20 0 0 0 0 0 0 0 0 0 0 033.2856-5.0152-7.9212-4.8471-4.7554-6.2842-4.5937-3.4997-2.62783.878519.443327.128633.2856QC'd by DC Chemicals
Activator125.892542.598721Partial curve; partial efficacy-3.93.51170.976137.4259-5.17282.20 0 0 0 0 0 0 0 0 0 0 035.6074-5.598-4.4535-4.6006-3.7313-6.9471-4.1018-8.894-6.2272-3.9162-0.216711.113435.6074QC'd by VWR
Activator89.125161.805321Partial curve; partial efficacy-4.052.25260.958363.8512.04572.20 0 0 0 0 0 0 0 0 0 0 056.34353.54612.34033.8269-0.5044-2.87860.16810.48344.07334.340220.973641.969856.3435QC'd by USP
Activator44.668433.361120Partial curve; partial efficacy-4.354.95490.928130.4844-2.87672.20 0 0 0 0 0 0 0 0 0 0 033.48350.7298-3.8211-2.4723-0.4853-2.48731.9269-1.5566-7.3972-6.9654-4.191314.437833.4835QC'd by SIGMA
Activator28.183859.492320Partial curve; partial efficacy-4.552.12110.981559.2264-0.26592.20 0 0 0 0 0 0 0 0 0 0 045.1170.14330.4757-1.1368-1.91440.9583-2.3049-1.3742-0.09592.436810.915519.43245.117QC'd by Specs
Activator22.387250.321220Partial curve; partial efficacy-4.652.33320.967848.961-1.36022.20 0 0 0 0 0 0 0 0 0 0 041.6305-1.0546-0.51781.05653.204-3.1958-2.6962-3.3382-2.3942-3.633510.231422.986341.6305QC'd by NIEHS
Activator22.387266.762120Partial curve; partial efficacy-4.652.04790.966765.0924-1.66972.20 0 0 0 0 0 0 0 0 0 0 053.3263-3.567-2.19723.9071-0.7451-1.2565-1.6762-4.72480.0598-4.496616.107630.04653.3263QC'd by NIEHS
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: DSHEA-v1-PXR-agonist-CTF
Protocol: For PXR luciferase reporter gene assays, we used hPXR-LucHepG2cells provided by Dr. Taosheng Chen (Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital). Cells were cultured in EMEM supplemented with 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin, and 500ug/mL of geneticin.

PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007) [1]
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 5 uL; hPXR-LucHepG2; white solid-bottom Greiner plate.
2; Incubation; 5h; 37C, 95% humidity, 5% CO2
3; Compounds and control; 23 nL; Kalypsis pintool (Wako USA).
4; Reagent; 1uL; rifampicin (RIF) in the antagonist mode.
5; Incubation; 24 hr; 37C, 5% CO2.
6; Reagent; 1 uL; CellTiter-Fluor detection reagent.
7; Incubation; 1 hr; 37C, 5% CO2.
8; Read; Fluorescence; ViewLux plate reader.
9; Reagent; 4 uL; ONE-Glo Luciferase detection reagent.
10; Incubation; 30 min; room temperature.
11; Read; Luminescence; ViewLux plate reader.

NOTES (numbers refer to Sequence numbers above)
1. Briefly, 5uL of hPXR-LucHepG2 cells in phenol red-free DMEM containing 5% charcoal-stripped FBS, 1 mM sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), and 100 U/mL penicillin and 100ug/mL streptomycin were dispensed using a BioRAPTR FRD at 4 x 105cells/mL (2000cells/well) in tissue culture-treated 1536-well white assay plates (GreinerBio-One).
2. Plates were incubated for 5h at 37C, 95% humidity, and 5% CO2 to allow for cell attachment.
3. Compounds (final concentration for most substances ranged from 15.6 nM to 45.9muM), positive control rifampicin (RIF; final concentration range of 2.8 nM to 92muM for the agonist mode), and cytotoxicity control tetraoctyl ammonium bromide (final concentration of 92muM) were transferred (23 nL) via pintool (Wako Automation).
4-5. After compound transfer, plates were dispensed with 1muL of the media in the agonist mode using a BioRAPTR FRD and incubated for approximately 24 h at 37 degrees C and 5% CO2.
6-8. Following incubation, 1uL of CellTiter-Fluor (Promega, Madison, Wisconsin) was added using a BioRAPTR FRD, after which all plates were incubated (37C/ 5% CO2) for 1 h and then measured for fluorescence intensity (Ex/Em= 405/540 nm) on a ViewLux plate reader to determine cell viability.
9-11. Directly after this fluorescence reading, 4uL of ONE-Glo Luciferasere agent (Promega) was added to each well using the BioRAPTR FRD, followed by a 30 min incubation (RT) and read for luminescence intensity on a ViewLux detector.

REFERENCES:
[1] Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
[2] Lin W, Wu J, Dong H, Bouck D, Zeng FY, Chen T. Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J Biol Chem. 2008 Nov 7;283(45):30650-7. doi: 10.1074/jbc.M806132200. Epub 2008 Sep 9. PMID: 18784074; PMCID: PMC2662154.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent agonists are ranked higher than compounds that showed apparent antagonist.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003880000 uMActivity at 0.00117 uMActivity at 0.00224 uMActivity at 0.00351 uMActivity at 0.00793 uMActivity at 0.011 uMActivity at 0.029 uMActivity at 0.045 uMActivity at 0.095 uMActivity at 0.189 uMActivity at 0.308 uMActivity at 0.821 uMActivity at 1.503 uMActivity at 2.601 uMActivity at 4.999 uMActivity at 8.318 uMActivity at 21.96 uMActivity at 40.04 uMActivity at 68.25 uMActivity at 121.3 uMActivity at 242.9 uMActivity at 565.0 uMActivity at 1133.4 uMActivity at 2258.3 uMActivity at 4077.1 uMActivity at 4590.0 uMCompound QC
Activator10Single point of activity00341.251116.813917.13085.80418.210214.6289.27613.99792.179316.701126.08719.50741.2511QC'd by Axon Medchem
Inhibitor25.118979.49940Partial curve; partial efficacy-4.61.88510.8809-80.4994-1-2.20 0 0 0 0 0 0 0 0 0 0 0-60.9844-8.3599-4.1108-0.3444-11.57673.51984.96689.57164.2331-17.2158-11.7715-39.1274-60.9844QC'd by Timtec
Inhibitor31.622895.56340Partial curve; partial efficacy-4.52.35310.8631-96.0634-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0-72.7753-6.8881-3.3208-3.076112.75391.9093-0.79046.82312.6146-7.9331-23.5282-18.0196-72.7753QC'd by Timtec
Inactive00043.91194.76885.58121.6514-8.3499.23334.32514.0356-0.3615-0.20432.6808-0.05673.9119QC'd by NIEHS
Inactive000418.652220.020718.124212.823317.177811.506418.62087.82268.595319.387611.249215.190218.6522QC'd by NIEHS
Inactive0004-11.0235-2.3288-4.9883-2.058-0.38911.1259-8.97082.0241-9.4201-17.1740.791-14.7061-11.0235QC'd by Labotest
Inactive000414.94214.331612.073613.839416.423416.703618.466110.421912.281514.093932.403514.704114.942QC'd by Microsource
Inactive0-4.81.34370.7327-16.04564.540 0 0 0 0 0 0 0 0 0 0 0-11.70460.8383.85191.95357.87343.649512.16163.08212.972-4.30770.1241-9.682-11.7046QC'd by SigmaAldrich
Inactive0-4.653.51170.4081-2.772715.540 0 0 0 0 0 0 0 0 0 0 0-0.643924.925419.07386.06058.42513.415214.919313.794910.669128.759616.52654.2985-0.6439QC'd by FLUKA
Inactive00049.865315.383915.794915.578215.8417.366323.775316.400716.948131.430234.187610.08299.8653QC'd by Timtec
Inactive0-5.44.95490.750319.50.154240 0 0 0 0 0 0 0 0 0 0 016.28962.35072.13075.21067.939-2.1412-1.3331-10.70490.36123.079919.405916.9116.2896QC'd by ASDI
Inactive00046.82660.56726.1190.08513.771-5.7981.34010.590111.032-3.46779.52992.45976.8266QC'd by SigmaAldrich
Inhibitor79.432851.08290Single point of activity-4.13.1320.677-54.5829-3.5-30 0 0 0 0 0 0 0 0 0 0 0-41.3507-6.1955-5.5479-3.6187-6.2729-3.8883-5.9198-10.8577-7.72274.9878-3.69855.5592-41.3507QC'd by SigmaAldrich
Inactive0-4.650.40.5286-34.1016-11.466340 0 0 0 0 0 0 0 0 0 0 0-26.6686-12.5178-8.3053-23.8027-16.0657-16.4067-11.8517-17.1711-20.3545-24.4433-18.1564-26.7513-26.6686QC'd by Enamine
Inactive0-5.34.95490.8647-29.0962-15.214140 0 0 0 0 0 0 0 0 0 0 1-21.5077-17.6173-18.2501-11.8451-14.8537-13.8162-13.1838-16.9815-24.3417-32.9968-29.0139-25.1086-21.5077QC'd by Enamine
Inactive0-5.14.95490.34640-5.205440 0 0 0 0 0 0 0 0 0 0 02.58220.981-6.223-5.7422-5.1579-4.8896-3.0017-9.3378-8.03122.34741.1285-5.59092.5822QC'd by Enamine
Inactive0-60.40.35621.5-11.481840 0 0 0 0 0 0 0 0 0 0 00.1828-6.6154-8.3148-15.81811.639-3.4473-7.9188-3.2712-2.5357-4.00081.1316-1.94090.1828QC'd by SIGMA
Inactive0-4.354.95490.7563-8.091740 0 0 0 0 0 0 0 0 0 0 02.7625-9.96-6.5741-10.0388-9.5144-5.5606-4.3237-10.9098-6.7845-8.0245-8.0118-1.73312.7625QC'd by SIGMA
Inactive0-50.50.61918-18.187840 0 0 0 0 0 0 0 0 0 0 1-16.5209-21.4065-10.9296-12.17-15.9227-14.8775-9.3127-3.8321-10.7718-11.73733.6244-0.1854-16.5209QC'd by LightBiologicals
Inactive0-5.350.40.5288-28.3571-8.718440 0 0 0 0 0 0 0 0 0 0 0-24.4642-11.2992-10.283-18.738-15.1055-5.5987-16.1145-24.2525-18.6306-20.4752-19.2793-22.796-24.4642QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:hedgehog, isoform A [Drosophila melanogaster]
External ID: 2070-01_Inhibitor_SinglePoint_HTS_Activity
Protocol: Protocol:
ASSAY PROCEDURE FOR HEDGEHOG AUTOPROCESSING

Buffer A: 20 mM sodium phosphate, pH 7.5, 0.5 M NaCl

Buffer B: 20 mM sodium phosphate, pH 7.5, 0.5 M NaCl, 8 M urea
This is prepared by adding 48 g of urea (enzyme grade) to 50 ml of double-strength Buffer A and adjusting volume to 100 ml with H2O.


Buffer D: 20 mM sodium phosphate, pH 7.0, 0.5 M NaCl, and 0.5 M arginine
(2.0 M arginine, pH 7.0, is prepared by dissolving 211 g of L-arginine hydrochloride (obtained from Research Organics) in 300 ml of H2O, adjusting pH to 7.0 with NaOH, and adjusting volume to 500 ml)



REAGENTS:
Urea - American Bioanalytical AB02100
Arginine Hydrochloride - American Bioanalytical AB000164
TCEP [Tris(2-carboxyethyl)phosphine hydrochloride] - Sigma C4706
DM-MEA [2-(Dimethylamino)ethanethiol] - Aldrich D141003 (very hygroscopic)
Cholesterol - Sigma C8667
FLAsH-EDT2-Invitrogen T34561

CELL DISRUPTION:

Suspend the cells from 50 ml of E. coli [Rosetta 2 (DE3)/pET45Dmel710#2] in 3 ml of Buffer A +
1 mM PMSF and disrupt by passing twice through the small French pressure cell. Centrifuge in 12 ml Sorvall tubes at 12,000 rpm for 30 min. and collect the pellet (inclusion bodies). The pellet is washed twice by resuspending in 4 ml of Buffer A + 1 mM PMSF and centrifugation at 12,000 rpm for 20 min. The pellet is then then resuspended in 3 ml of Buffer B + 1 mM PMSF to extract the inclusion bodies and centrifuged at 12,000 rpm for 20 min. Save the supernatant and extract the pellet a second time with 3 ml of Buffer B + 1 mM PMSF and combine the supernatants. Centrifuge the combined supernatants in the Sorvall at 18,000 rpm for 60 min to remove insoluble material and yield the solubilized inclusion bodies (IB). Save inclusion bodies at 4 degrees C after diluting about 10% with Buffer A to avoid crystallization of urea.

Typically, the protein concentration of the inclusion bodies is 1 mg/ml. The material is stable on storage at 4 degrees C for at least a month and can be kept frozen at -80 degrees C in 1 ml portions indefinitely.


Dilution Buffer:
297 ml of Buffer D
3 ml of 0.1 M TCEP
300 ml Final

Substrate mix
6.5 ml of 26 mM cholesterol in 95% EtOH
2.0 ml of 1% Triton X-100
41.5 ml of H2O
50 ml + 200 ml Dilution Buffer (cholesterol = 680 microM) - Dilute immediately before use

Control mix
0.8 ml of 1% Triton X-100
19.2 ml of H2O
20 ml + 80 ml Dilution Buffer (No cholesterol)

IB mix
13.2 ml Hedgehog protein ( approximately 1.65 mg/ml) [12 ml form prep of 10.05.11, 2 ml from prep of 10.05.10]
198 ml Buffer D (
room temp)
2.2 ml of 0.1 M TCEP
2.2 ml of 0.1 M DM-MEA
2.2 ml of 0.17 mM FlAsH
2.2 ml of H2O
220 ml final




Incubate at 25*C for 2 h. Dialyze against 3 X 1 liter Buffer D + 1 mM TCEP (10 ml of 0.1 M TCEP per liter) for 6 h - 14h. Recommended dialysis tubing: SpectraPor MWCO 8,000, flat width = 12 mM (VWR 25223-650). Readjust volume to 220 ml after dialysis.The dialyzed Hh Protein Cocktail can be stored at 4 degrees C for at least 5 days with negligible loss of activity. It should be stable at room temperature for at least 12 h.




Dispense 35 microl per well. Add IB mix first to entire plate. Wait 30 min before adding cholesterol, while control mix (35ul) is added to columns 23&24.

Then add substrate mix to columns 1-22, 40 min after adding protein. Fluorescence polarization was measured after 1 hour incubation at 25C using Tecan Safire 2 microplate reader (Tecan, Mannedorf, Switzerland) with excitation at 390 nm and emission at 550
nm.
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control wells (PC) were included on every plate.

EXPECTED OUTCOME: Active compounds result in increasing readout signal.

NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Neutral Controls Minus Inhibitors' method in Genedata Assay Analyzer (v7.0.3):
The median raw signal of the intraplate neutral control wells was set to a normalized activity value of 0.
The median raw signal of the intraplate positive control wells was set to a normalized activity value of -100.
Experimental wells values were scaled to this range.

PATTERN CORRECTION: No plate pattern correction algorithm from Genedata Condoseo (v.7.0.3) was applied.

PUBCHEM_ACTIVITY_SCORE:
This was set as equal to the mean of the normalized sample replicate activities, rounded to the nearest integer .
The minimum PUBCHEM_ACTIVITY_SCORE required for a compound to be called a hit (the activity threshold, or AT) was set to be three standard deviations above the mean neutral control value.

PERCENTAGE OF ACTIVE REPLICATES:
For each sample, the percentage of replicates (PCT_ACTIVE_REP) which had activity scores >= AT was determined.
The minimum percentage of replicates required for a compound to be called a hit (PAR_T) was set at -50.

PUBCHEM_ACTIVITY_OUTCOME:
Samples passing BOTH threshold criteria were assigned an outcome of 2 (active):
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP >= PAR_T

Samples passing NEITHER threshold criteria were assigned an outcome of 1 (inactive):
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP < PAR_T

Samples passing AT only were assigned an outcome of 2 (active) :
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP < PAR_T

tSamples passing PAR_T only were assigned an outcome of 2 (active) :
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP >= PAR_T
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_30.34uM_(%)REPLICATE_B_ACTIVITY_SCORE_30.34uM_(%)
0.9766013.0438.333
0.9926013.04316.667
0.959409.09116.667
0.9991018.18216.667
0.7071009.091
0.707108.3330
0.9594016.6679.091
0.95940-16.667-9.091
0.999108.3339.091
0.999108.3339.091
0.999108.3339.091
0.707108.3330
0.987802518.182
108.3338.333
0.948708.33316.667
1016.66716.667
1016.66716.667
0.948708.33316.667
0.9914021.73916.667
0.9991018.18216.667
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SMAD3201
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. Two uL of CellTiter Glo (Promega), a luminescence-based viability reagent, was dispensed, followed by a 10 minute room temperature incubation. The plates were then measured on a PerkinElmer ViewLux plate reader for luminescence (clear filter) using a 5 second exposure. The %Activity was determined from the corrected luminescence values. Wells containing media only (no cells) were used to normalize %Activity of identified toxic compounds; media-only wells corresponded to 100%Activity (complete cell-killing), while DMSO-dosed cell controls were used to normalize 0%Activity (no toxicity).

Concentration-response curves were fitted to the signals arising from the resulting luminescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Toxic compounds showed concentration-dependent decreases in luminescence, concordant with a decrease in intracellular ATP concentration (CellTiter Glo's marker of viability), and thus a decrease in the number of viable cells. Inactive (non-toxic) compounds showed no effect on luminescence signal. Active (toxic) compounds showed concentration dependent decrease in luminescence.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".

2. For all inactive (non-toxic) compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active (toxic) compounds, a score range was given for each curve class type given above. Active (toxic) compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.233 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 00.259610.7694.1255-1.6909-0.74870.2596QC'd by "Chem Div"
Inactive40 0 0 0 0-0.8876-5.2018-3.67070.33032.9155-0.8876QC'd by "Chem Div"
Inactive40 0 0 0 0-4.2306-10.0984-0.7957-0.93222.0609-4.2306QC'd by "Chem Div"
Inactive45.8218-1.6618-3.05539.7773-4.1735.8218QC'd by "Chem Div"
Inactive4-3.265111.605-17.88485.978514.3087-3.2651QC'd by "Chem Div"
Inactive40 0 0 0 0-7.2413.20083.9728-4.51213.9811-7.241QC'd by "Chem Div"
Inactive40 0 0 0 0-9.8078.98690.34840.37287.0197-9.807QC'd by "Chem Div"
Cytotoxic17.782835.5846Partial curve; partial efficacy-4.752.30310.9974-42.6167-7.0321-2.20 0 0 0 0-39.1036-6.2767-6.4175-8.2439-13.6777-39.1036QC'd by "Chem Div"
Cytotoxic3.548140.0619Single point of activity-5.454.95490.8999-40.3659-0.3039-30 0 0 0 12.6367-8.3337.8061-1.7484-40.23322.6367QC'd by "Chem Div"
Inactive40 0 0 0 10.54241.65919.664714.274915.58960.5424QC'd by "Chem Div"
Inactive40 0 0 0 05.9628-8.298-2.31046.1361-3.44285.9628QC'd by "Chem Div"
Inactive40 0 0 0 0-1.0151-4.6247-5.8885-4.492-0.7127-1.0151QC'd by "Chem Div"
Inactive4-0.9022-1.288913.9053-1.0794.3101-0.9022QC'd by "Chem Div"
Inactive40 0 0 0 0-23.5202-1.57517.1469-12.67219.6037-23.5202QC'd by "Chem Div"
Inactive40 0 0 0 1-0.075-0.6173-0.87325.1352.1913-0.075QC'd by "Chem Div"
Cytotoxic35.481333.3813Single point of activity-4.454.95490.4913-37.3813-4-30 0 0 0 0-30.3178-0.6381-23.6633-3.83866.0591-30.3178QC'd by "Chem Div"
Inactive40 0 0 0 0-17.4140.1464-4.8771-5.0687-7.6162-17.414QC'd by "Chem Div"
Inactive4-4.6673-7.1501-3.3264-4.1232-3.249-4.6673QC'd by "Chem Div"
Inactive40 0 0 0 0-17.38786.57262.9374-7.8375-3.1433-17.3878QC'd by "Chem Div"
Inactive40 0 0 0 1-10.2269-7.0609-5.5812-5.82172.0518-10.2269QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Peroxisome proliferator-activated receptor gamma
External ID: CHEMBL2014330
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 7
First Page: 2527
Last Page: 2533
DOI: 10.1016/j.bmcl.2012.01.136

Target ChEMBL ID: CHEMBL235
ChEMBL Target Name: Peroxisome proliferator-activated receptor gamma
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
22.6EC50=22600nM
3.6EC50=3600nM
19.3EC50=19300nM
52.3EC50=52300nM
48.7EC50=48700nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL2014328
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 7
First Page: 2527
Last Page: 2533
DOI: 10.1016/j.bmcl.2012.01.136
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
60EC50>60000nM
10.3EC50=10300nM
ActivityDose-dependent effect
6.2EC50=6200nM
ActivityDose-dependent effect
2EC50=2000nM
ActivityDose-dependent effect
4.3EC50=4300nM
ActivityDose-dependent effect
60EC50>60000nM
ActivityDose-dependent effect
ActivityDose-dependent effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Peroxisome proliferator-activated receptor alpha
External ID: CHEMBL2014329
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 7
First Page: 2527
Last Page: 2533
DOI: 10.1016/j.bmcl.2012.01.136

Target ChEMBL ID: CHEMBL239
ChEMBL Target Name: Peroxisome proliferator-activated receptor alpha
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
60EC50>60000nM
4EC50=4000nM
ActivityDose-dependent effect
ActivityDose-dependent effect
19.5EC50=19500nM
ActivityDose-dependent effect
46.1EC50=46100nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:cystic fibrosis transmembrane conductance regulator [Homo sapiens]
External ID: SBCCG-A764-CF-PAF-Primary-Assay
Protocol: Assay Materials:
KKLEB-NFkB-GFP cells (Assay Provider)
PAF(Assay Provider)
Fetal Bovine Serum (Hyclone SH30396.03)
Penicillin Streptomycin solution
L-glutamine (100X)
TrypLE (Invitrogen 12563)
DPBS without calcium and magnesium (1X)
Corning culture flasks
Black CellBind 1536-well plates (Corning 3833)
ATPlite (Perkin Elmer 6016739)

I. Cell Suspension
1- Dispense 3 uL/well of cells at 5X10;5 cells/mL to the whole plate (plate cells in 2% FBS assay media).
2- Spin down plates on Eppendorf centrifuge 5810 at 500 rpm for 1 minute.

II. Compound Addition:
3- Transfer test compounds to columns 5-48 and DMSO to columns 1-4 using the Labcyte ECHO 555.
4- Transfer volume of test compound and DMSO is 15nL, making 5uM compound concentration at 0.25% DMSO final.
5-Spin down plates on Vspin at 1000 rpm for 1 minute.
6-Put Kalypsys metal lids on plates, incubate plates at 37 degrees C with 5% CO2 for 2 hours.

III. Reagent Addition
7- Dispense 3 uL/well of serum free assay media to columns 1 and 2.
8- Dispense 3 uL/well of PAF (dilute in serum free assay media) to columns 3-48.
9- Spin down plates without lids on Vspin at 2000 rpm for 2 min
10- Put Kalypsys metal lids on plates, and incubate plates at 37 degrees C with 5% CO2 overnight.

IV. Reading plates:

11-Spin plates upside down with a container at 1000 rpm for 15 sec. Dab them with a tissue to dry them and Read immediately on envision for GFP fluorescence.
12-Dispense 6 uL/well of ATPlite (diluted in DPBS 1:1).
13-Spin down plates on Eppendorf centrifuge 5810 at 2000 rpm for 2 minutes without lids.
14-Incubate plates for 10 min at RT and run Luminescence read on Viewlux.
Comment: Compounds that demonstrated a corrected %Activity of >= 50% at 5 uM concentration are defined as actives in this assay.

The experimental values were normalized by the difference between values from neutral and stimulator control wells in each plate. Then normalized data was corrected to remove systematic plate patterns due to artifacts such as dispensing tip issues etc. Further information about data correction is available at http://www.genedata.com/products/screener.html.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary and single-concentration confirmation screening data.
a. If outcome of the primary screen is inactive, then the assigned score is 0
b. If outcome of the primary screen is inconclusive, then the assigned score is 10
c. If outcome of the primary screen is active, then the assigned score is 20
d. If outcome of the single-concentration confirmation screen is inactive, then the assigned score is 21
e. If outcome of the single-concentration confirmation screen is inconclusive, then the assigned score is 25
f. If outcome of the single-concentration confirmation screen is active, then the assigned score is 30.
This scoring system helps track the stage of the testing of a particular SID. For the primary hits which are available for confirmation, their scores will be greater than 20. For those which are not further confirmed, their score will stay under 21.

2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues and is not applicable in this assay
%Activity at 5 uMValueMean LowStd Deviation LowMean High Std Deviation High
17.71388986164067.888625.22080144.63200104.91
-5.52023753164067.888625.22080144.63200104.91
-1.91947331164067.888625.22080144.63200104.91
4.91776516164067.888625.22080144.63200104.91
4.41681435164067.888625.22080144.63200104.91
7.11654104164067.888625.22080144.63200104.91
-16.92220014164067.888625.22080144.63200104.91
5.51825441164067.888625.22080144.63200104.91
-10.22135725164067.888625.22080144.63200104.91
13.11722580164067.888625.22080144.63200104.91
0.11996001164067.888625.22080144.63200104.91
-1.51994666164067.888625.22080144.63200104.91
12.61687553164067.888625.22080144.63200104.91
-12.42138337164067.888625.22080144.63200104.91
1.91864558164067.888625.22080144.63200104.91
14.31574274164067.888625.22080144.63200104.91
20.41414289164067.888625.22080144.63200104.91
67.4531762164067.888625.22080144.63200104.91
3.11778225164067.888625.22080144.63200104.91
53.5823431164067.888625.22080144.63200104.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_ANT_FLUO8_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as antagonists and decrease activity of the human M1 muscarinic receptor (CHRM1; M1) that have been pre-treated with a known agonist, with the end result being a decrease in intracellular calcium. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye. Compounds are added followed by treatment with the activator acetylcholine at a concentration that results in 80% activation (Ec80). As designed, compounds that act as CHRM1 antagonists will decrease calcium mobilization, resulting in decreased relative fluorescence of the indicator dye below that of the Ec80 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470 - 495 nm excitation and 515 - 575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC80 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay.

Hits for this assay were determined according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and,
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent inhibition was calculated from the median ratio as follows:

%_Inhibition = ( 1 - ( Ratio Test_Compound - Median_Ratio_High_Control ) / ( Median_Ratio_Low_Control - Median_Ratio_High_Control ) ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Ec80 of acetylcholine and DMSO.
High_Control is defined as wells containing DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-7, and for inactive compounds 80-0.

In this assay not all plates were run in the same batch. This resulted in batch-to-batch variation among the different batches of plates, thereby necessitating the use of a plate-based activity cutoff. For this reason the inactive and active scores overlap.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3 uM
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.47
6.47
6.47
6.47
6.47
6.47
6.47
6.47
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Smad3 [Homo sapiens]
External ID: SMAD3101
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. The plates were measured on an Acumen eX3 Explorer plate reader for GFP fluorescence (ex488/em500-530). GFP values were calculated by determining the mean GFP fluorescence of individual cells, and compiling these values for each well to determine a total well GFP signal. The %Activity was determined from the corrected fluorescence values. A titration of the known TGF-B inhibitor SB431542 was included to monitor plate performance, while unstimulated HEPG2 (-TGF-B) control wells were used to normalize %Activity of identified inhibitors; unstimulated wells corresponded to 100%Activity (full inhibition), while stimulated cell controls (+DMSO) were used to normalize 0%Activity (no inhibition).

Concentration-response curves were fitted to the signals arising from the resulting fluorescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Active inhibitors showed concentration-dependent decreases in GFP fluorescence, concordant with a decrease in TGF-B/SMAD3-driven GFP expression. Inactive compounds showed no effect on fluorescence signal.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.231 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 027.05699.939810.15150.16715.572127.0569QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-4.9362-9.41412.0824-11.0493-7.696-4.9362QC'd by "Asinex Ltd."
Inactive40 0 0 0 15.95954.342-1.5624-2.6449-8.95385.9595QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-19.7473-1.4487.5701-38.1554-17.3097-19.7473QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.2351-5.5487-5.0573-16.62112.7653-1.2351QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.1959-7.76824.48993.399213.37077.1959QC'd by "Asinex Ltd."
Inactive40 0 0 0 18.983315.3354.25354.1946-14.32368.9833QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.9022-10.517413.4936-10.46867.23237.9022QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-11.834712.2839-2.7256-19.2666-5.8034-11.8347QC'd by "Asinex Ltd."
Inhibitor35.4813106.2444Single point of activity-4.454.44950.9934-109.7251-3.4808-30 0 0 0 0-84.6645-7.4849-2.0755-4.81140.1432-84.6645QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.6-2.07174.941415.4055-0.2463-3.6QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.7641028.345612.16980.90780.7641QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-3.7338-9.95590.39868.925512.5033-3.7338QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.77973.8831.182-4.1851.7497-1.7797QC'd by "Asinex Ltd."
Inhibitor15.848938.9608Single point of activity-4.83.67720.9889-35.46083.5-30 0 0 0 0-32.8842.06775.8192.7318-1.3119-32.884QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.7978.4821-2.183612.765.4907-3.797QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-18.74991.02723.81520.51991.7606-18.7499QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.46409.4101-6.52060.90670.464QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.23719.7122-4.6112-6.6419-3.28890.2371QC'd by "Asinex Ltd."
Inactive40 0 0 0 13.67994.89241.7621-1.6686-4.49453.6799QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cutibacterium acnes
External ID: CHEMBL1006951
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 1994
Volume: 57
Issue: 1
First Page: 9
Last Page: 17
DOI: 10.1021/np50103a002

Target ChEMBL ID: CHEMBL612639
ChEMBL Target Name: Cutibacterium acnes
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=400ug.mL-1
MIC>800ug.mL-1
MIC=400ug.mL-1
MBC=800ug ml-1
MIC>400ug.mL-1
MIC=200ug.mL-1
MIC=200ug.mL-1
MIC=3.13ug.mL-1
MBC=6.25ug ml-1
MIC=100ug.mL-1
MBC=200ug ml-1
MIC=200ug.mL-1
MIC=400ug.mL-1
MIC=25ug.mL-1
MBC=50ug ml-1
MIC=12.5ug.mL-1
MBC=25ug ml-1
MIC=6.25ug.mL-1
MIC=200ug.mL-1
MIC=25ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR985
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.5265-7.1483-6.3353-8.6464-2.6851-3.55893.2191-3.1242-5.8134-5.6348-5.47660.4473-0.0628-2.5265QC'd by SIGMAInactive0-4.274510.6363
Inactive00043.9024-0.01911.091.23652.36520.00372.0670.4851-0.4224-1.0393-0.4413.17850.34623.9024QC'd by SigmaAldrichInactive0
Inactive00040.8889-4.98190.1870.7854-0.1677-2.0871-0.80150.24410.7043-8.80280.1379-2.37921.85830.8889QC'd by ChemServiceInactive0-7.06644.95490.4482
Inhibitor50.390553.327221Partial curve; partial efficacy-4.29773.06540.9802-53.3433-0.0161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8509-1.3968-0.7491.0621-2.87011.05283.12180.0760.9249-0.49840.7261-1.3704-19.9808-46.8509QC'd by SigmaAldrichInactive0
Inhibitor70.827737.733910Partial curve; partial efficacy; poor fit-4.14981.46410.7102-39.7339-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.77821.0091-5.79512.7551.2254-6.9293.33021.728-8.1392-0.7165-6.4259-8.7096-8.3826-29.7782QC'd by SigmaAldrichInhibitor70.827741.854910Single point of activity-4.14984.50450.8302
Inhibitor61.503849.916621Partial curve; partial efficacy-4.21113.1320.892-53.3018-3.3852-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2741-8.1807-7.61190.23321.57810.17121.3858-3.7535-3.206-6.6036-4.2950.0288-15.3692-42.2741QC'd by SIGMAInactive0
Inhibitor52.384150.532421Partial curve; partial efficacy-4.28082.40640.9534-51.6847-1.1523-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.2915-0.3854-0.06330.2042-1.816-8.719-1.02010.9052-1.1643-1.4537-2.6853-2.4432-20.0028-40.2915QC'd by SIGMAInhibitor58.775939.524221Partial curve; partial efficacy-4.230810.8135
Inactive0004-9.709-4.4881-6.0445-8.8766-4.0388-0.5862-4.6549-8.3113-5.6134-4.8338-4.5642-0.5579-3.4555-9.709QC'd by Alfa AesarInactive0-4.15283.990.694
Inactive00041.66471.2462-0.14863.91093.85360.66890.332-0.85721.14780.26430.82850.06271.34331.6647QC'd by SV ChembiotechInactive0-4.16373.92950.6564
Inactive0-6.2164.95490.70982-6.490740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5913-5.6041-9.9923-0.3428-7.6059-8.1832-4.6842-7.94470.1162.2630.2481.13570.77486.5913QC'd by SigmaAldrichInactive0
Inactive0-4.16644.95490.6737-25.7581-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.0484-0.84940.9603-8.21540.11392.05482.69681.41610.7927-9.70141.13732.2368-2.4398-21.0484QC'd by ChemServiceInactive0-4.36642.33320.8792
Inactive0-8.56773.1320.69960.5-9.217540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1871-8.0979-1.72310.81240.29791.59360.956-0.5761.2867-4.1414-0.48432.01310.0104-0.1871QC'd by SIGMAInactive0
Inactive00045.07940.37572.19050.57630.92270.78453.46994.04961.90151.38273.96340.9117-0.60225.0794QC'd by SIGMAInactive0-4.96862.40640.6273
Inactive0-6.16074.95490.57915.5-2.430540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1812-3.6421-0.044-0.36213.4152-5.3209-0.5383-7.85872.63685.21583.6992.344410.63857.1812QC'd by City ChemicalInhibitor54.870797.99941Partial curve; high efficacy-4.26071.78850.9628
Inactive0004-7.623-2.2142-5.4178-2.8594-1.2478-3.2961-1.8162-3.3949-3.2651-2.4468-13.60120.62040.0323-7.623QC'd by SIGMAInactive0
Inactive0-7.13754.0950.34570-4.700140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0759-3.7616-3.6914-6.6307-6.3734-2.2758-1.4469-2.07440.5601-2.1426-0.4933-0.57645.1155-1.0759QC'd by SIGMAInactive0-4.58753.29750.926
Inactive0-6.92270.30.66969.5-12.317940 0 0 0 0 0 0 0 0 0 0 0 0 0 010.1368-8.154-8.9165-0.0326-1.7004-6.75864.0282-0.75942.5751-1.1314-0.72269.25986.41410.1368QC'd by SIGMAActivator26.751674.08270Partial curve; high efficacy-4.57272.18760.9777
Inactive0-8.31644.95490.36241-4.006940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.262-4.04751.1113-0.82860.46322.60630.59311.42180.5483-1.23861.81471.70282.46480.262QC'd by SIGMAInactive0-8.81644.95490.6203
Inactive0-4.86070.50.827124-3.343540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.3215-3.1196-2.8382-4.3087-0.9342-1.40680.1964-2.25525.21846.34245.162110.173116.8440.3215QC'd by LKT LabActivator9.757633.8970Complete curve; partial efficacy-5.01073.06540.9367
Inactive0-7.82850.70.757422.5-441 0 0 0 0 0 0 0 0 0 0 0 0 0 13.832412.68164.022614.57444.428120.650914.83922.328422.246920.362223.860820.325322.23313.8324QC'd by SIGMAInactive0-4.42850.80.8451
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR504
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator0.769618.541110Partial curve; partial efficacy; poor fit-6.11370.40.4771201.45892.40 0 0 0 0 0 0 0 0 0 1 1 1 1 18.43542.60297.16556.98426.77576.23584.39893.727414.10836.104412.34916.28710.24048.4354QC'd by SIGMAInactive0-7.46371.10.4107
Activator0.001518.544Complete curve; partial efficacy-8.81374.95490.845716.5-21.20 0 0 0 0 0 0 0 0 0 0 1 0 1 112.76338.520316.029918.960814.610214.569714.66815.484519.340417.405215.435716.74874.776812.7633QC'd by AcrosInactive0
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4538.53828.60629.13179.549110.755911.43756.467911.275510.13049.21297.3275-0.1191-11.453QC'd by SIGMAInactive0-4.36422.40640.8668
Inactive000417.43489.84064.73143.893717.43064.73392.71741.799421.142216.61518.79213.32233.134217.4348QC'd by Sigma DiscoveryCPRInactive0
Inactive000417.41599.11946.7603-2.39424.5125-5.07691.71712.688120.52570.113721.134-0.09350.75717.4159QC'd by EnamineInactive0-4.46372.35310.6137
Inactive0-8.51372.40640.34146.5-2.869340 0 0 0 0 0 0 0 0 0 0 0 0 0 09.2286-0.79294.86514.6489.82256.79684.62743.882111.065210.47076.49230.8715-0.7419.2286QC'd by SIGMAInactive0
Inhibitor3.063824.51160Complete curve; partial efficacy; poor fit-5.51374.95490.4049-18.61465.897-1.40 0 0 1 1 0 0 0 0 0 0 0 0 0 0-11.6821-3.038721.1044-20.78423.7169-18.207310.98469.041514.7886-15.2892-21.1562-17.0848-22.0042-11.6821QC'd by SIGMAInactive0
Activator0.001935.242610Complete curve; partial efficacy; poor fit-8.71424.95490.546629.4733-5.76921.40 0 0 0 0 0 0 0 0 0 0 1 1 1 1-35.059810.398831.296228.151536.89384.846829.689133.269131.780835.498622.02484.7913-29.1164-35.0598QC'd by SIGMAInactive0-4.31423.51170.6226
Inactive0004-0.31614.47693.98640.77972.2321.48744.16990.43690.07470.80680.3965-3.2133-3.9851-0.3161QC'd by SIGMAInactive0-4.71374.95490.3304
Inhibitor54.482733.50530Partial curve; high efficacy-4.26373.92950.9608-34.0053-0.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.00440.50840.4104-0.8948-3.2842-0.42840.0932-3.308-1.82040.56451.2561.479-9.8714-30.0044QC'd by Sigma DiscoveryCPRInhibitor68.589649.00410Single point of activity-4.16374.50450.9035
Inactive0-6.31374.95490.40220.5-2.854340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9062-1.42020.2852-3.8028-4.0452-3.8452-3.7145-3.80550.63741.33431.7137-3.28390.5803-2.9062QC'd by MP BiomedicalsInactive0
Inhibitor61.130658.88120Partial curve; high efficacy-4.21373.19250.9781-59.7265-0.8453-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.5201-0.605-1.4306-2.7189-0.8465-0.0963-1.1087-1.55290.5068-0.225-0.0391-7.585-12.7325-47.5201QC'd by SIGMAInhibitor61.130669.99940Partial curve; partial efficacy-4.21373.990.9846
Inhibitor48.508455.41370Partial curve; high efficacy-4.31423.06540.992-53.97671.437-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.95211.59250.5164-0.94190.64010.73652.10781.92572.71730.23973.6782-1.5898-20.1662-46.9521QC'd by SIGMAInhibitor54.427380.68770Partial curve; high efficacy-4.26422.47290.9773
Inactive00041.1920.359-0.3975-0.251.0086-0.1111.15210.61861.1885-1.45780.6853-0.92120.6021.192QC'd by SIGMAInactive0
Inactive00040.2182-3.0991-1.93151.3572-2.42631.55190.1835-0.68480.605-0.3437-2.1085-0.74640.05991.72430.2182QC'd by LightBiologicalsInactive0
Activator68.589630.210110Single point of activity-4.16373.24750.923330-0.210130 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8495-0.3001-1.0271-2.0701-0.01770.97450.4274-1.8475-0.9875-0.00953.49112.8063.96521.8495QC'd by SIGMAInactive0-4.46371.92820.7837
Activator17.228923.958720Partial curve; partial efficacy-4.76370.60.7544240.04132.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.99880.30040.8704-1.63220.2766.3859-0.80141.77834.025210.31816.43328.494618.8419-1.9988QC'd by LightBiologicalsActivator24.336535.974310Single point of activity-4.61374.0950.8673
Inactive00040.8624-0.4215-2.3373-2.43560.2408-1.76690.8666-1.7395-2.0022-1.4521-1.4395-0.981-0.53890.8624QC'd by LightBiologicalsInactive0-4.51374.95490.8869
Inactive0-4.11374.95490.654990.039740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5998-0.8326-1.8287-1.08391.30271.03891.22330.81780.8549-1.37240.03750.73910.19056.5998QC'd by SIGMAInactive0-4.56374.95490.8448
Inactive0-4.56374.50450.4774.5-1.13740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.7168-1.8447-2.9517-3.0308-1.8846-0.48982.2361-1.7012-0.2024-2.7129-0.6292-0.32113.7485-3.7168QC'd by SIGMAInactive0-4.11374.95490.7344
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Bacillus subtilis
External ID: CHEMBL957747
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL359
ChEMBL Target Name: Bacillus subtilis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=400ug.mL-1
MIC=800ug.mL-1
MIC=400ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC=400ug.mL-1
MIC=400ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=50ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cutibacterium acnes
External ID: CHEMBL957749
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL612639
ChEMBL Target Name: Cutibacterium acnes
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=200ug.mL-1
MIC=200ug.mL-1
MIC=50ug.mL-1
MIC=50ug.mL-1
MIC=200ug.mL-1
MIC=50ug.mL-1
MIC=100ug.mL-1
MIC=100ug.mL-1
MIC=800ug.mL-1
MIC=50ug.mL-1
MIC=50ug.mL-1
MIC=6.25ug.mL-1
MIC=800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Corynebacterium ammoniagenes
External ID: CHEMBL957748
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL613079
ChEMBL Target Name: Corynebacterium ammoniagenes
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=400ug.mL-1
MIC=800ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=200ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC=100ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mus musculus
External ID: CHEMBL827544
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2005
Volume: 15
Issue: 7
First Page: 1949
Last Page: 1953
DOI: 10.1016/j.bmcl.2005.01.070

Target ChEMBL ID: CHEMBL375
ChEMBL Target Name: Mus musculus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=15%
Inhibition=15%
Inhibition=15%
Inhibition=7%
Inhibition=27%
Inhibition=3%
Inhibition=24%
Inhibition=19%
Inhibition=1%
Inhibition=43%
Inhibition=27%
Inhibition=1%
Inhibition=-4%
Inhibition=6%
Inhibition=11%
Inhibition=0%
Inhibition=-1%
Inhibition=-3%
Inhibition=1%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Saccharomyces cerevisiae
External ID: CHEMBL957755
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL361
ChEMBL Target Name: Saccharomyces cerevisiae
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=400ug.mL-1
MIC=800ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC=200ug.mL-1
MIC=3.13ug.mL-1
MIC=200ug.mL-1
MIC=800ug.mL-1
MIC=800ug.mL-1
MIC=50ug.mL-1
MIC=50ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR163
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00043.0633-0.75412.1391.5904-0.3839-1.1415-0.39720.3007-0.97562.17540.8962-0.70775.67143.0633QC'd by ACCInactive0-4.475110.3403
Inactive0-4.47512.58840.5668.5-0.350840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.86480.1037-0.8896-0.4598-1.86570.62930.11860.461.3225-4.0423-0.7584-0.26931.61755.8648QC'd by ACCInactive0-4.87510.96410.6959
Inconclusive26.603243.928410Partial curve; high efficacy-4.57511.75290.950842-1.92842.10 0 0 0 0 0 0 0 0 0 0 0 0 0 032.0411-4.94030.1803-1.7907-1.04840.7187-2.0655-1.6464-0.9268-3.163-1.69577.805612.275332.0411QC'd by ACCInconclusive14.960143.862810Partial curve; partial efficacy-4.82511.96730.9669
Inactive0-4.77511.17050.46487-2.090540 0 0 0 0 0 0 0 0 0 0 0 0 0 05.8087-2.6379-0.128-0.3535-5.64580.03570.6444-4.5926-6.7421-1.9435-0.94861.98431.17355.8087QC'd by ACCInactive0-9.12514.95490.3263
Inactive00041.42561.18570.65356.04820.39286.34775.07265.4272.92610.04150.34843.0231-0.03451.4256QC'd by RTIInactive0
Inactive0004-1.88582.35057.09190.33143.3965-1.34684.203-0.8178-0.3747-1.06299.6715-2.4181-0.776-1.8858QC'd by RTIInactive0
Inactive0410.19018.95610.325512.63911.810913.69999.62495.66968.687812.306313.512815.91738.562510.1901QC'd by RTIInactive0
Inactive0004-0.41364.053-1.44611.85171.21114.06523.09290.81280.93140.5931-2.12422.4304-0.681-0.4136QC'd by RTIInactive0
Inactive00040.842-0.47542.86752.25690.4215-1.5297-2.07673.62060.9619-1.5025.02941.288-1.44990.842QC'd by RTIInactive0
Inconclusive0.00215.510Complete curve; partial efficacy; poor fit-8.70534.50450.795614-1.51.40 0 0 0 0 0 0 0 0 0 0 1 1 0 1-9.16440.693913.915611.436716.139211.324915.416415.994911.157614.795712.415311.295913.1797-9.1644QC'd by RTIInactive0-4.10534.95490.806
Inactive0004-6.75480.2459-1.60532.34130.73913.9972-1.3651-1.7233-3.4099-1.711.5906-2.29334.2594-6.7548QC'd by RTICytotoxic74.351433.63620Partial curve; partial efficacy; poor fit-4.12874.0450.7048
Cytotoxic40.421673.990940Partial curve; high efficacy-4.39342.25260.9604-70.17013.8208-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.09312.03564.92412.49064.22714.26826.20750.1594-0.95685.63330.0103-1.2879-37.614-61.0931QC'd by RTICytotoxic50.887883.280741Partial curve; high efficacy-4.29342.40640.9709
Cytotoxic69.171880.051341Partial curve; high efficacy-4.16014.50450.9543-74.39445.6568-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.67343.72427.29138.5895.08398.48319.02366.00472.81232.47474.97363.2009-4.4556-62.6734QC'd by RTICytotoxic69.171870.875120Single point of activity-4.16014.95490.9592
Inactive00045.1373.18785.21485.1644.96454.2219-0.33642.43436.57815.74133.06254.20694.86615.137QC'd by RTIInactive0
Cytotoxic78.824137.545620Single point of activity-4.10334.95490.8973-36.54561-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.20472.52230.11410.250.7493-2.2911-0.3071-0.86864.6455-1.007-1.8243.89684.0876-29.2047QC'd by RTICytotoxic78.824134.719820Partial curve; partial efficacy; poor fit-4.10334.95490.8207
Cytotoxic54.894739.278640Partial curve; high efficacy-4.26053.1320.9761-38.27861-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.1488-1.31041.12321.8921-0.72281.240.11850.53022.330.65950.21212.9868-14.3497-33.1488QC'd by RTICytotoxic54.894761.362221Partial curve; partial efficacy-4.26052.18760.9745
Inactive00043.14233.21915.8769-1.7146-0.4681-0.26044.11687.43091.98552.08331.94551.2669-1.29783.1423QC'd by RTIInactive0
Inactive0004-2.77945.33392.168-2.2813-0.6736-2.0788-16.89162.24013.5698-1.00744.02973.9198-1.0474-2.7794QC'd by RTIInactive0-4.79590.40.487
Inactive0004-0.88360.18994.02715.7421-2.1210.15651.51726.95692.32841.27492.76063.93542.593-0.8836QC'd by RTIInactive0
Inactive0-6.964110.3333-0.776340 0 0 0 0 0 0 0 0 0 0 0 0 0 13.24412.13982.31925.45162.7289-2.13923.47190.2244-0.6655-1.88570.9391.8723-2.31343.2441QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Klebsiella aerogenes
External ID: CHEMBL957754
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL612508
ChEMBL Target Name: Klebsiella aerogenes
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:firefly luciferase
External ID: LUC790
Protocol: Tox21 Assay Protocol Summary:

3 ul of substrate mix (containing 50 mM Tris acetate, pH 7.6, 13.3 mM Mg acetate, 10uM D-luciferin, 10uM ATP, 0.01% Tween, 0.05% BSA and dH2O ) is dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS.) 1 uL of firefly luciferase mix (containing 50 mM Tris acetate, pH 7.6, 0.04 uM P. pyralis luciferase, 0.01% Tween, 0.05% BSA and dH2O) was then delivered by FRD to each well. Luciferase activity was then measured using a ViewLux CCD imager.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000074871 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000679832 uM-Replicate_1Activity at 0.0001616562 uM-Replicate_1Activity at 0.0003744726 uM-Replicate_1Activity at 0.0007728037 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00651 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.2010.90.8471131.115440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.54731.4227-0.0927-0.73721.51692.33370.74961.98550.53323.45031.33282.53683.90686.069.5473QC'd by LightBiologicalsActivator70.63415.92510Partial curve; partial efficacy; poor fit-4.1510.90.7402
Inactive00043.83132.48656.35684.00543.84138.25791.63143.11833.93691.19885.93977.44213.27273.8313QC'd by LightBiologicalsInactive0
Inhibitor27.540425.239720Partial curve; partial efficacy-4.563.06540.9464-24.23971-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.86643.54850.58071.273.5792-1.0506-0.74551.82640.64041.29330.55871.0439-10.0294-21.8664QC'd by LightBiologicalsInactive0-4.364.50450.8982
Inhibitor70.574761.494341Partial curve; high efficacy-4.15142.30310.9936-61.34170.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.84970.69220.24130.03541.62351.4902-0.6178-0.2576-0.1338-0.7741-1.5037-5.7105-17.9277-46.8497QC'd by LightBiologicalsInhibitor62.899858.392741Partial curve; high efficacy-4.20143.1320.9871
Inactive0-4.39890.90.710380.988440 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7160.31890.18581.95122.60040.67990.14231.73831.70660.79292.27513.9265.04871.716QC'd by LightBiologicalsInactive0
Inactive0004-1.2464-0.1277-3.31990.07610.0272-0.171-0.9426-1.275-0.8314-1.0122-0.1704-0.7926-0.2083-1.2464QC'd by LightBiologicalsInactive0
Inactive00049.0594-4.22375.94818.69258.92016.96137.5769-4.56141.7618.73328.6084-3.34-3.90129.0594QC'd by LightBiologicalsInactive0
Inactive00041.81981.5048-2.86521.29632.0381-3.75161.90181.93420.96122.92531.90792.69043.8991.8198QC'd by LightBiologicalsInactive0-4.19893.92950.4592
Inactive00041.0427-2.9040.2976-1.36752.4811.58460.60181.9111.8233-2.31412.7932-0.1252-3.80621.0427QC'd by LightBiologicalsInactive0
Inactive00041.81572.32444.23827.73370.21471.78012.640.32671.7625.77573.74973.61055.36231.8157QC'd by LightBiologicalsInactive0-4.51490.50.3892
Inhibitor89.358431.923510Single point of activity-4.04894.95490.9445-30.92351-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.10290.8105-1.44111.7887-0.1850.69522.96312.16590.03891.2506-0.78660.32282.6099-24.1029QC'd by LightBiologicalsInhibitor89.358427.433610Single point of activity-4.04894.95490.9335
Inactive0-6.39480.90.42680.05953.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.61711.84673.25183.75243.33334.00713.8712-0.9505-1.43963.0690.48362.44510.1858-1.6171QC'd by LightBiologicalsInactive0
Inactive00040.0907-0.4901-3.2387-0.7092-0.3212-0.94770.426-0.2568-0.3555-0.5594-0.8083-0.44290.5340.0907QC'd by LightBiologicalsInactive0
Inactive00040.8222.29930.05141.4340.8292-3.84692.04270.53252.7743.15713.841.89041.86440.822QC'd by LightBiologicalsInactive0
Inhibitor79.640758.055341Partial curve; high efficacy-4.09893.62720.9858-58.8675-0.8123-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8693-1.39271.2532-1.8476-3.00891.0377-0.085-0.0864-1.0068-0.2868-1.8043-4.6859-9.7906-46.8693QC'd by LightBiologicalsInhibitor70.979924.628520Partial curve; partial efficacy-4.14893.57220.9379
Inactive0-4.04894.50450.8551-8.6034140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.33621.44610.98591.11170.77190.52781.33360.63411.98470.66550.3564-1.19960.4705-6.3362QC'd by LightBiologicalsInactive0-4.24891.46410.7616
Inhibitor31.705522.975520Partial curve; partial efficacy-4.49892.09370.9159-21.97551-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.22960.1079-1.25660.0804-0.4464-0.9265-0.24241.22035.1564-0.16970.1335-8.2794-14.2156-21.2296QC'd by SIGMAInhibitor39.914927.035120Partial curve; partial efficacy-4.39891.47870.9029
Inactive00041.68681.80593.04642.90412.6745-1.14845.3851.35853.20093.01323.66774.258211.12191.6868QC'd by SIGMAInactive0
Inactive0004-0.01532.91587.60184.7593.8923-5.03062.21774.13765.41963.00133.93875.23166.3628-0.0153QC'd by SIGMAInhibitor89.358418.599210Partial curve; partial efficacy; poor fit-4.04894.95490.8509
Inactive00043.7853-0.6681.31811.1372-0.42441.41111.52592.25831.1924-5.84795.2943-0.63157.19593.7853QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Malassezia furfur
External ID: CHEMBL960282
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL612926
ChEMBL Target Name: Malassezia furfur
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=100ug.mL-1
MIC=400ug.mL-1
MIC=100ug.mL-1
MIC>800ug.mL-1
MIC=200ug.mL-1
MIC=100ug.mL-1
MIC=50ug.mL-1
MIC=100ug.mL-1
MIC=400ug.mL-1
MIC=100ug.mL-1
MIC=200ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cyberlindnera jadinii
External ID: CHEMBL957756
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL612309
ChEMBL Target Name: Cyberlindnera jadinii
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=400ug.mL-1
MIC=400ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC=200ug.mL-1
MIC=6.25ug.mL-1
MIC=200ug.mL-1
MIC=800ug.mL-1
MIC=800ug.mL-1
MIC=200ug.mL-1
MIC=100ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Streptococcus mutans
External ID: CHEMBL957751
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL612426
ChEMBL Target Name: Streptococcus mutans
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=200ug.mL-1
MIC=400ug.mL-1
MIC=400ug.mL-1
MIC>800ug.mL-1
MIC=400ug.mL-1
MIC=100ug.mL-1
MIC=200ug.mL-1
MIC=400ug.mL-1
MIC>800ug.mL-1
MIC=100ug.mL-1
MIC=100ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR541
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO, was added using a Flying Reagent Dispenser to generate a final concentration of 50 nM CITCO inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inhibitor3.349141.215910Single point of activity-5.47514.95490.5085-42.7363-1.5203-30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-8.087121.89-8.6781-3.6855-6.25695.4433-2.2253-6.5947-10.7583-4.5705-16.1608-16.3686-5.5938-8.0871QC'd by ACCInactive0
Inhibitor2.660331.350422Complete curve; partial efficacy-5.57514.95490.7593-35.7832-4.4328-1.20 0 0 0 0 0 0 0 0 0 0 0 0 1 1-7.07487.0287-3.7117-8.93987.0191-8.6003-10.5811-9.6323-3.5772-9.7824-21.4714-32.0269-13.6825-7.0748QC'd by ACCInactive0
Inhibitor29.8493180.333140Partial curve; high efficacy-4.52511.86170.9403-183.9808-3.6476-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-139.3794-6.9891-4.5485-2.48725.72942.1105-4.4422-5.01950.98326.5263-18.8291-30.3545-53.8001-139.3794QC'd by ACCInhibitor29.8493162.790140Partial curve; high efficacy-4.52513.24750.9553
Inactive0-4.77512.40640.4777-19.93010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.4418-5.3665-6.0776-0.6378-0.7746-5.95928.056814.4063-4.2029-2.83313.6942-1.1786-14.0414-17.4418QC'd by ACCInactive0-4.57513.1320.6731
Inactive0-4.04014.95490.487724-5.718340 0 0 0 0 0 0 0 0 0 0 0 0 0 017.6907-9.6058-16.8485-11.179-0.45450.0756-9.022-7.6078-4.898-2.6992-0.66814.3314-11.422917.6907QC'd by RTIActivator64.553243.03530Partial curve; partial efficacy-4.19013.92950.9117
Inactive0004-19.84863.3433-23.4364-34.1329-6.2414-5.0556-25.546-8.9103-6.9329-28.1976-6.81633.8592-42.036-19.8486QC'd by RTIActivator67.057937.01130Partial curve; partial efficacy; poor fit-4.17353.67720.7941
Inactive0-4.02734.95490.655322-3.294740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.0345-2.80161.8842-7.0081-1.7985-7.3345-5.4629-6.0156-0.7765-1.4972-8.9956-1.9725-7.487516.0345QC'd by RTIInactive0-4.27732.33320.6095
Inactive00047.8644-12.2433-5.1181-4.04961.28844.3493-4.5231-6.8637-4.8147-7.4445-2.1022-11.7632-20.07367.8644QC'd by RTIInactive0-4.37991.96730.5769
Inactive000412.77776.2553-5.7998-3.9544-6.27073.8508-4.3153-0.2911-4.79463.74813.8044.64191.374312.7777QC'd by RTIInactive0-4.28464.95490.3638
Inactive0-4.20534.44950.6434-17.42521.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.7713.79853.86442.4904-4.2833.78225.42352.6092-2.38-3.39182.70615.627-2.5037-15.771QC'd by RTIInactive0-5.20534.95490.321
Inhibitor5.9059106.654984Complete curve; high efficacy-5.228710.9844-102.49964.1553-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.8049.49943.6503-0.42471.07452.82466.38180.0721-15.1461-24.7454-55.3584-79.6141-94.3827-85.804QC'd by RTIInhibitor4.691398.416784Complete curve; high efficacy-5.32870.90.9674
Inactive0-4.69341.55790.702223-4.449740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3595-2.1806-3.3591-6.2651-0.28090.121-6.0475-11.7066-7.89250.86856.2708-0.375526.069416.3595QC'd by RTIActivator71.880946.06290Single point of activity-4.14344.95490.7673
Inhibitor69.1718135.093943Partial curve; high efficacy-4.16013.06540.9789-149.2252-14.1313-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-117.8714-2.1311-17.2291-13.9078-13.6919-19.6465-13.3695-15.7919-17.4807-14.0473-10.7354-16.145-44.1916-117.8714QC'd by RTIInhibitor54.9451147.633342Partial curve; high efficacy-4.26012.40640.9628
Inactive0-6.14174.95490.4637-11.0778-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.73651.2389-2.2448-12.4683-0.62132.0757-1.40511.6174-8.0337-11.8106-11.9614-1.3448-17.9815-2.7365QC'd by RTIInactive0-4.34170.50.4602
Inhibitor8.844263.970182Complete curve; high efficacy-5.05331.46410.9355-69.4155-5.4454-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.4281-3.3461-7.3817-5.25411.5957-7.1494-6.1151-2.5632-12.7008-17.0044-40.829-49.2957-77.8583-59.4281QC'd by RTIInhibitor7.882431.683321Complete curve; partial efficacy-5.10332.33320.905
Inhibitor19.477457.938541Partial curve; partial efficacy-4.71051.34430.9334-57.56260.376-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.0338-12.41210.71942.24359.20663.0773-1.07773.1429-3.055-5.8935-11.5387-32.2284-42.404-52.0338QC'd by RTIInhibitor77.540938.538210Single point of activity-4.11054.95490.5991
Inactive0004-3.3574-9.0659-5.0523-7.9611.8345-6.6475-6.4054-4.0807-7.994-5.2589-4.8636-18.8381-16.5327-3.3574QC'd by RTIInactive0-5.70264.95490.3553
Inactive0-4.09594.95490.659231.5-0.506240 0 0 0 0 0 0 0 0 0 0 0 0 0 025.14185.9174-1.2243-9.58850.3121-2.79136.44825.5515-1.4762-0.4167-3.92814.3971-4.45225.1418QC'd by RTIActivator56.764849.34910Partial curve; partial efficacy-4.24591.80790.7545
Inactive000411.60064.5643-3.7194-10.097311.42282.41525.31161.6689-4.6133-3.7747-3.13611.8656-13.87311.6006QC'd by RTIInactive0-4.14513.29750.4562
Inactive0-4.06414.95490.569122-3.35640 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3590.1187-1.3367-4.6228-5.1472-1.2162-0.1657-0.04880.0689-5.7723-5.23-1.7902-11.963316.359QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL957750
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR611
Protocol: Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195, was added using a Flying Reagent Dispenser to generate a final concentration of 0.75 uM PK11195 inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.36620.69570.44051.11090.5787-0.2699-0.32331.18450.0326-1.0092-1.73120.8267-2.1104-2.3662QC'd by SigmaAldrichInactive0
Inactive0004-0.2849-0.47850.10371.13040.3494-1.2942-2.3851-1.60740.1233-0.8459-1.8941-2.6451-0.2138-0.2849QC'd by SigmaAldrichInactive0
Activator53.984430.302520Partial curve; partial efficacy-4.26772.04370.980730-0.30252.20 0 0 0 0 0 0 0 0 0 0 0 0 0 022.9705-0.53970.19140.0778-0.1425-0.2776-1.9188-0.46281.1362-0.8514-0.42823.186710.348822.9705QC'd by SigmaAldrichActivator27.056334.152540Partial curve; high efficacy-4.56771.47810.9607
Inactive0-7.768610.69720.758810.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.08229.0278.56537.5724.21540.90080.24680.02675.66910.0433-7.0E-4-2.28440.3557-1.0822QC'd by SIGMAInactive0
Activator17.351737.620340Partial curve; high efficacy-4.76073.06540.989337.3935-0.22682.10 0 0 0 0 0 0 0 0 0 0 0 0 0 124.0027-1.13920.1686-0.1252-1.4390.2351-0.49480.65421.28420.05961.310721.815534.209324.0027QC'd by SIGMAActivator4.890445.728181Complete curve; high efficacy-5.31070.70.9547
Inactive00040.5220.023-1.1865-1.4762-0.05160.6407-0.0477-0.5943-1.0553-3.4872-1.7526-1.5011-0.45170.522QC'd by SIGMAInactive0-5.56914.95490.4552
Inactive0-4.27133.29750.65377-0.991840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.71270.1065-2.9589-3.3265-0.1367-0.53720.1194-0.7792-2.1668-3.2131-0.01280.58790.97235.7127QC'd by SigmaAldrichInactive0-4.12134.95490.6439
Inactive0004-4.945-2.5611-5.5604-5.5744-3.7841-2.51970.8205-4.2283-4.7634-6.5963-6.2633-3.1896-5.8718-4.945QC'd by SIGMAInactive0
Inactive0-4.16290.60.42327-1.160340 0 0 0 0 0 0 0 0 0 0 0 0 0 04.3597-0.362-3.0077-3.05030.2438-1.01930.3335-0.4699-1.28130.401-0.46414.3554-0.91184.3597QC'd by SIGMAInactive0-5.51292.33320.8433
Inactive0004-0.70380.0361-3.7089-1.7915-1.25830.16870.69770.1566-2.4696-3.4971-1.51-1.5395-3.4697-0.7038QC'd by SIGMAInactive0
Inactive0004-1.2777-1.6943-2.5955-3.5033-1.64891.17161.2363-2.1104-2.9787-3.3438-1.1157-1.1422-1.1735-1.2777QC'd by SIGMAInactive0
Inactive0004-0.56630.288-2.3707-2.7283-0.63382.07513.38390.0802-2.4707-3.83610.0879-0.2454-2.8389-0.5663QC'd by SIGMAInactive0-4.85851.88510.9504
Inactive0004-1.1005-0.9792-1.7954-2.6037-0.12-0.26040.3413-0.8959-1.9784-3.2297-1.6711-0.0062-3.6975-1.1005QC'd by SIGMAInactive0
Inactive0004-1.2459-4.784-9.0537-2.2125-3.0446-0.91621.9784-0.3992-6.2878-10.5833-9.5972-2.1042-10.227-1.2459QC'd by SIGMAInactive0
Inactive0004-1.0084-1.7104-1.9369-2.0369-1.6802-0.573-0.47480.085-2.3375-4.3727-2.4796-2.5942-2.7424-1.0084QC'd by SIGMAInactive0
Inactive0004-0.9643-2.3604-0.8724-2.1936-0.583-0.2670.1582-0.3325-2.7466-3.9462-1.2392-0.1393-2.9256-0.9643QC'd by SigmaAldrichInactive0
Inactive0004-6.2696-3.3484-4.8795-5.0177-4.9214-3.95680.8092-3.9748-5.0443-6.7588-5.093-3.1627-6.7773-6.2696QC'd by ChemServiceInactive0
Inactive0004-3.7787-1.21870.3496-1.1618-0.178-0.02990.1049-1.7277-1.4204-3.3075-1.8639-0.2976-4.4158-3.7787QC'd by SIGMAInactive0
Inactive0004-5.5543-3.7243-4.3348-6.0183-4.46860.85250.2555-1.1073-5.5639-6.2665-7.6529-4.829-7.4675-5.5543QC'd by SIGMAInactive0
Activator21.579778.216381Complete curve; high efficacy-4.6662.47290.975179.1210.90471.10 0 0 0 0 0 0 0 0 0 0 0 0 0 079.9059-0.6357-0.03330.1670.65420.84030.39860.65146.9793-1.6191.148938.519460.089479.9059QC'd by FisherActivator24.212873.718240Partial curve; high efficacy-4.6161.10.9797
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Pseudomonas aeruginosa
External ID: CHEMBL957753
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL348
ChEMBL Target Name: Pseudomonas aeruginosa
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR224
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195 (final concentration = 0.75 uM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.7001-2.07971.16113.0882-0.077102.1698.77392.9614-2.21710.116619.58354.13960.7001QC'd by ACCInactive0-4.52511.10.5248
Inactive00046.4354-1.02440.0097-0.0933-1.85581.1884-0.92732.35142.15013.76020.1771-1.03550.10946.4354QC'd by ACCInactive0
Inconclusive14.960164.783610Partial curve; high efficacy-4.82511.55790.966665.88741.10382.10 0 0 0 0 0 0 0 0 0 0 0 0 0 064.59921.6564-1.48951.3624-0.33672.53023.07761.2257-1.3673-1.46236.837225.336734.910764.5992QC'd by ACCInconclusive29.849380.826810Partial curve; high efficacy-4.52512.25260.8962
Inactive00047.00811.6498-1.43860.50060.40820.79470.89650.34840.35820.30331.35526.99592.91727.0081QC'd by ACCInactive0
Inactive00043.05635.54866.72620.53512.71380.70682.23040.2851-1.53215.16263.86991.54890.8433.0563QC'd by RTIInactive0
Inactive00040.74666.36313.94348.84614.56211.575.48974.19182.16295.86320.50451.34453.99310.7466QC'd by RTIInactive0
Inactive00040.67381.12332.28591.01811.5966-0.43621.77940.2945-1.37111.71640.89490.65662.50770.6738QC'd by RTIInactive0
Inactive00041.00343.59883.74021.61832.4828-24.1996-11.8417-15.26063.54570.8131-0.0321-11.9734-1.31061.0034QC'd by RTIInactive0
Inactive0-4.18464.95490.9125-10.752.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.31021.06850.91324.13362.67391.81972.26761.87431.57794.70882.78081.3363-11.4583-9.3102QC'd by RTIInactive0-3.83464.50450.8486
Inactive0-4.15534.95490.6213-8.5472540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7063.03746.28947.39888.83679.30074.16635.48521.16012.64973.10975.62653.3473-6.706QC'd by RTIInactive0-4.50531.13410.921
Inactive0-4.07872.90230.7611-27.65215.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.71016.68477.71693.3955.081315.63232.80533.07480.28617.9345.15692.3389-1.44-19.7101QC'd by RTICytotoxic74.351457.123720Single point of activity-4.12872.90230.9124
Cytotoxic57.09755.000921Partial curve; partial efficacy-4.24343.57220.9446-54.11980.881-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.68171.44960.64610.87374.0413-0.6397-8.70514.50811.25313.61011.83811.5671-14.0711-46.6817QC'd by RTICytotoxic57.09772.527141Partial curve; partial efficacy-4.24342.35310.9803
Cytotoxic69.1718108.736442Partial curve; high efficacy-4.16012.63840.9717-107.06951.6669-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.11334.12134.26247.21762.32561.1447-8.56171.58873.20240.90921.8827-6.6983-25.0645-81.1133QC'd by RTICytotoxic54.9451118.001241Partial curve; high efficacy-4.26012.12110.9982
Inactive00041.23831.33150.88153.39274.07264.82921.16914.05412.98531.32630.32392.28032.47551.2383QC'd by RTIInactive0
Cytotoxic62.612238.428920Partial curve; partial efficacy; poor fit-4.20332.53340.9423-35.92892.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.44074.56793.2733.0004-0.82787.03151.32971.03340.94391.5864-0.53831.1816-10.0481-27.4407QC'd by RTICytotoxic55.803256.613421Partial curve; partial efficacy-4.25332.53340.9455
Cytotoxic34.636240.085420Partial curve; partial efficacy-4.46052.78680.9485-35.58544.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-37.55547.86573.08136.25493.50321.57814.64299.84995.08361.63343.0637-4.2032-21.4975-37.5554QC'd by RTICytotoxic48.92563.310741Partial curve; partial efficacy-4.31052.40640.966
Inactive0-4.95263.51170.4728-12.1793140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.88662.10451.60872.2705-1.9686-0.7779-1.63741.02741.49992.1762.5-23.0661-2.7817-0.8866QC'd by RTIInactive0-4.15262.63840.6052
Inactive0004-2.84033.5493.05938.34540.08545.4167-0.89290.03223.37180.29422.8684-1.08252.444-2.8403QC'd by RTIInactive0-4.09594.95490.8672
Inactive00040.57120.96791.09642.61560.08615.51343.14970.57852.83021.933.1832-1.67453.16860.5712QC'd by RTIInactive0
Inactive0-4.51414.95490.6339-9.2283240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.63681.3480.78612.61030.0177-0.69933.3843-0.57490.00933.38765.62053.6707-9.3569-0.6368QC'd by RTICytotoxic68.537737.040120Partial curve; partial efficacy; poor fit-4.16412.90230.9194
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Escherichia coli
External ID: CHEMBL957752
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL354
ChEMBL Target Name: Escherichia coli
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC=400ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC=400ug.mL-1
MIC=200ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR404
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO (final concentration = 50 nM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-1.2885-8.2133-8.16350-7.1502-6.0582-1.0685-6.9497-7.74221.4318-0.484-9.89-5.9739-1.2885QC'd by LightBiologicalsInactive0
Inactive0-4.21374.50450.3794-2.0019-11.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.2267-13.6359-11.5589-12.427-11.9862-12.3014-2.0849-11.776-12.2205-11.2807-10.5655-12.6043-10.0799-3.2267QC'd by SIGMAInactive0
Inactive0004-18.8355-16.5392-15.7843-14.6365-14.6435-14.8247-15.1826-17.2997-17.0567-15.571-15.4498-16.8771-18.7769-18.8355QC'd by SIGMAInactive0
Cytotoxic61.130668.499141Partial curve; partial efficacy-4.21373.57220.9855-82.6763-14.1772-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.8305-13.3313-15.7246-16.9851-15.1291-16.6431-12.0943-15.0603-13.2228-10.6311-12.392-15.5076-28.0786-69.8305QC'd by SIGMACytotoxic61.130688.918141Partial curve; high efficacy-4.21372.47290.9648
Inactive0004-9.4937-8.4802-2.4154-6.8019-7.6968-8.7013-4.9931-5.9136-8.161-5.4834-5.5854-7.8666-8.6242-9.4937QC'd by LightBiologicalsInactive0-8.06374.95490.5744
Inactive0-4.21373.29750.784-19.65540.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.54620.30110.54811.68972.3515-1.76286.6762-2.18030.3036-2.6294-0.6711-0.2348-3.468-15.5462QC'd by SIGMAInactive0-4.21370.40.6227
Inactive0004-0.8117-4.0669-9.8967-11.0574-6.4365-5.9282-6.3535-7.6972-5.2867-9.8338-1.3993-0.8947-7.6295-0.8117QC'd by SIGMAInactive0
Cytotoxic61.503855.678321Partial curve; partial efficacy-4.21113.990.9569-57.7149-2.0366-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-48.64770.26981.6175-2.9758-3.96481.7183-4.47090.3089-5.9715-1.9196-1.5152-1.5012-11.187-48.6477QC'd by ChemServiceInactive0-4.21114.95490.8972
Inactive0-4.11374.95490.6896-23.3009040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.75070.5104-1.55631.8378-3.19332.5092-0.693-8.08051.92620.04853.9244-2.18611.6782-17.7507QC'd by SIGMAInactive0-4.21374.0950.6638
Cytotoxic60.5715107.680742Partial curve; high efficacy-4.21771.86170.9797-127.4822-19.8016-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.5775-19.6657-16.6526-20.809-21.6607-19.7704-14.2217-18.8965-22.5975-21.7271-20.6249-34.5795-53.8367-96.5775QC'd by EPACytotoxic42.8813102.238741Partial curve; high efficacy-4.36771.96730.9874
Cytotoxic34.201550.561640Partial curve; partial efficacy-4.4661.46410.9284-54.0991-3.5375-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.0918-2.7848-1.0730.0864-3.1155-8.38860.2833-5.2666-5.937-8.2702-10.3681-18.193-25.3466-50.0918QC'd by CrescentCytotoxic30.482144.89120Partial curve; partial efficacy-4.5161.47810.9399
Inactive0-3.96370.80.6909-31.6-3.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23-4.3769-2.78840.141-3.552-4.8242-6.7976-4.9877-2.8309-6.1986-3.8792-6.6066-8.0591-23QC'd by Sigma DiscoveryCPRCytotoxic61.130637.500120Single point of activity-4.21373.62720.9475
Inactive00042.7896-2.2890.3967-3.4023-0.5931-3.73261.98680.266-0.04370.42130.10770.45910.0122.7896QC'd by SIGMAInactive0
Inactive00040.26690.57262.32333.2007-0.42921.18692.47032.29592.39542.45931.99820.27692.75730.2669QC'd by SIGMAInactive0
Inactive00040.15290.81242.78170.7373.17970.4171.1829-3.29880.4225-0.650.0220.90230.99470.1529QC'd by SIGMAInactive0
Inactive0-4.11374.95490.7475-10.5412240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.11761.66523.16792.25360.69250.89822.26921.6541.01862.7189-0.12983.29222.2598-7.1176QC'd by SIGMAInactive0-4.56374.50450.3801
Inactive0004-3.2742-0.57391.18390.6992-0.1356-0.9956-3.9472-0.31020.02640.46931.55660.2082-3.8232-3.2742QC'd by SIGMAInactive0
Inactive0004-0.7927-6.5931-0.004-0.87430.5458-3.7497-2.0427-2.5866-3.6954-3.9867-18.7143-2.0222.5912-0.7927QC'd by SIGMAInactive0
Inactive0004-13.9982-8.8449-6.7122-3.2554-8.551-4.4661-2.4558-5.8647-10.1231-5.4289-3.8809-5.1227-8.4815-13.9982QC'd by SIGMAInactive0
Inactive0004-0.2549-3.2147-2.0568-1.3426-0.21941.32071.5504-1.1495-1.6104-0.5283-1.0103-2.0348-1.3745-0.2549QC'd by LightBiologicalsInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC875
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.3468-0.10070.0358-0.33470.23222.509-4.5860.2540.48071.16460.75384.1574-4.8525-0.3468QC'd by SIGMAInactive0
Inactive0004-3.3197-5.6995-7.8071-6.0662-4.9082-8.0484-7.708-4.8984-5.8365-2.5967-1.1821-5.7986-3.0963-3.3197QC'd by SigmaAldrichInactive0
Inactive00041.84520.97091.1435-0.24060.0731-0.12051.2062-0.18330.0921.20720.47061.31020.49521.8452QC'd by SIGMAInactive0-4.01730.70.5777
Inhibitor34.131725.96160Partial curve; partial efficacy-4.46682.33320.9617-25.96160-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.9681.69630.1516-1.09160.4925-0.73560.52772.66582.0E-4-2.8872-3.0257-4.5147-15.6179-24.968QC'd by SIGMAInhibitor48.212321.71050Partial curve; partial efficacy-4.31681.82650.8711
Inactive00041.39531.94521.30180.9104-0.31670.42261.07071.9713-0.37872.93970.83462.12710.21931.3953QC'd by SigmaAldrichInactive0
Inactive0-4.06334.95490.4301-7.0921-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.24341.0247-0.6334-0.0593-0.5529-0.870.3563-3.05990.0772-2.04451.2375-0.9179-0.0839-4.2434QC'd by SIGMAInactive0-4.31333.51170.5308
Inactive0-5.75854.95490.3744-2.0452140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.39762.44991.9442.7333-0.72910.18521.02430.39980.1524-5.0377-4.45790.10940.3382-0.3976QC'd by SigmaAldrichInactive0
Inactive00044.02841.30910.502-2.96730.6114-3.0343-5.43691.67780.79992.43120.8290.0491.04384.0284QC'd by Alfa AesarInactive0
Inactive0-5.26464.95490.4346-2.0801140 0 0 0 0 0 0 0 0 0 0 0 0 0 11.98340.29922.4906-0.22330.3752.7141.88570.4384-0.23811.8609-3.01220.5146-3.40011.9834QC'd by SIGMAInactive0
Inactive00042.63350.03471.26840.123-0.3218-0.7076-0.30731.1541.4491.46540.89010.0407-0.34962.6335QC'd by SIGMAInactive0
Inactive0-4.09724.95490.45685-0.300340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4899-1.55050.48970.6246-0.8749-0.70910.3983-0.38271.38450.1489-2.3336-0.5514-0.29293.4899QC'd by SigmaAldrichInactive0
Activator42.573923.761320Partial curve; partial efficacy-4.37091.46410.9148240.23872.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.55410.00531.42-0.16480.3750.50141.6438-0.125-0.76833.78914.61832.97299.933520.5541QC'd by SIGMAActivator60.13733020Partial curve; partial efficacy-4.22092.53340.9705
Inactive00042.55290.4063-0.01020.18952.3191-1.84951.7387-1.9418-1.54353.99270.02911.34360.7672.5529QC'd by SIGMAInactive0-8.36331.28760.3456
Inactive00041.41240.5842.30430.55631.00343.2421-0.03291.7832-2.03062.37860.03731.3846-0.48531.4124QC'd by ChemServiceInactive0
Inactive00043.2372-0.06260.30520.0902-0.17460.25520.3996-0.2881.25733.132-0.27620.86140.24633.2372QC'd by SIGMAInactive0
Inactive00042.54410.50790.20260.3539-0.13770.985-0.3504-1.23841.32581.2338-2.15810.15631.45512.5441QC'd by SIGMAInactive0
Inactive0-4.17223.67720.6648-5.8375140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.03120.75431.06750.67620.09292.30830.48760.50432.7882-0.24950.6636-0.05580.1164-4.0312QC'd by City ChemicalInactive0
Inhibitor17.334135.94590Complete curve; high efficacy-4.76113.1320.981-35.94590-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.7947-1.1822-0.3985-2.19492.5399-2.8881-1.15330.37421.44382.4728-1.8207-20.2287-32.2128-36.7947QC'd by InterchemInhibitor15.44939.10510Complete curve; high efficacy-4.81112.33320.9633
Inactive0-4.17994.0950.4925-4.84510.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.62090.76960.04541.12750.09010.13020.2945-0.00821.2284-0.19962.4956-2.29050.011-3.6209QC'd by SIGMAInhibitor46.785537.00050Partial curve; partial efficacy-4.32991.69240.9362
Inactive0004-3.6855-2.20722.44460.09531.2718-2.0196-1.5529-1.1351-0.9412-2.5691-0.9983-2.4138-2.9275-3.6855QC'd by SIGMAActivator5.431631.161281Complete curve; high efficacy-5.26511.34430.9707
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: TSHR942
Protocol: Tox21 Assay Protocol Summary:

TSHR-Hek293 cells were dispensed at 800 cells/4uL/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool, followed by 1 ul medium containing Ro20-1724. The plates were incubated at room temperature for 30 min. 2.5 ul/well of cAMP-d2 and 2.5ul/well of anti-cAMP-cryptate was added respectively into the assay plates using a Flying Reagent Dispenser. After 1 hr incubation at room temperature, the fluorescence intensity in the plates was measured using an Envision plate reader. Each test compound was measured at 15 concentrations and in triplicates.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W615-Activity_Score-Replicate_1W615-Curve_Description-Replicate_1W615-Fit_LogAC50-Replicate_1W615-Fit_HillSlope-Replicate_1W615-Fit_R2-Replicate_1W615-Fit_InfiniteActivity-Replicate_1W615-Fit_ZeroActivity-Replicate_1W615-Fit_CurveClass-Replicate_1W615-Excluded_Points-Replicate_1W615-Max_Response-Replicate_1W615-Activity at 0.0000060039 uM-Replicate_1W615-Activity at 0.0000137707 uM-Replicate_1W615-Activity at 0.0000545120 uM-Replicate_1W615-Activity at 0.0001296300 uM-Replicate_1W615-Activity at 0.0003002588 uM-Replicate_1W615-Activity at 0.0006197232 uM-Replicate_1W615-Activity at 0.00170 uM-Replicate_1W615-Activity at 0.00522 uM-Replicate_1W615-Activity at 0.013 uM-Replicate_1W615-Activity at 0.030 uM-Replicate_1W615-Activity at 0.068 uM-Replicate_1W615-Activity at 0.153 uM-Replicate_1W615-Activity at 0.349 uM-Replicate_1W615-Activity at 1.067 uM-Replicate_1W615-Activity at 3.267 uM-Replicate_1W615-Activity at 8.386 uM-Replicate_1W615-Activity at 18.95 uM-Replicate_1W615-Activity at 42.46 uM-Replicate_1W615-Activity at 92.41 uM-Replicate_1W615-Activity at 240.3 uM-Replicate_1W615-Activity at 872.4 uM-Replicate_1W615-Activity at 1849.0 uM-Replicate_1W615-Activity at 4135.0 uM-Replicate_1W615-Activity at 9246.0 uM-Replicate_1W615-Activity at 20670.0 uM-Replicate_1W615-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100046.71165.91411.01090.48573.26231.84362.00641.99435.44978.12683.9593.84525.64976.711610004-2.748
Inactive100041.15973.45360.9481-0.52418.4135-5.3381-0.2037-1.12098.426911.44892.56851.52615.51131.159710004-0.2798
Inactive1000413.619319.24979.80112.092519.851720.559717.738615.489515.20168.327325.730421.994613.226513.619310004-8.0616
Inactive10004-0.01774.084512.92615.3982.40380.8257.68639.482714.70655.1151-0.75927.9425-1.263-0.017710004-2.1171
Inactive100043.1252.35685.09388.475210.98810.10777.68738.07633.86263.49345.21091.85468.95053.12510004-15.6867
Inactive100047.46870.77720.070411.33447.3155.46854.97583.73919.3253-1.65574.71633.480410.62097.468710-8.61680.30.3731-11.65381840 0 0 0 0 0 0 0 0 0 0 0 0 0 12.1384
Inactive10-5.36373.51170.3912-2-8.811940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.9865-8.0324-8.6353-2.0989-6.6589-13.3952-12.0664-9.0355-11.3374-6.2204-1.73390.0195-5.6888-2.986510004-24.5166
Activator37.79197.19310004-6.7723-1.27140.9157-4.0255-10.6032-5.96680.5902-3.4901-1.7017-13.963-2.6223-0.0117-2.2437-6.77230Partial curve; high efficacy-4.42261.22210.920696.8641-0.32892.10 0 0 0 0 0 0 0 0 0 0 0 0 0 081.1085
Inactive100041.5703-3.83490.9073-2.0903-1.2647-1.4311-3.4337-4.0019-0.4467-1.59621.99851.4791-3.3903-4.9221.570310004-4.9352
Inconclusive10004-0.6217-8.1939-9.7496-1.3131-1.96560.67370.907-13.3517-7.4235-3.3313-2.5924-1.9513-5.0812-0.62170Partial curve; partial efficacy; poor fit-4.51371.62590.7426-35.2959-4-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.4966
Inactive10004-0.97-4.3623-1.46539.6687-8.1041-8.3111-5.9686-3.301-4.21888.9934-5.42630-0.6903-0.9710004-9.314
Inactive10004-1.4457-6.89480.2171-2.9459-4.0435-7.3456-1.1919-9.5752-2.6175-0.3368-10.17-0.6414-0.3902-1.445710004-2.246
Activator9.678780.70610004-5.3519-9.0236-6.6327-5.8557-0.1803-16.2183-5.9643-10.6841-5.3049-7.3617-3.4598-16.9691-11.695-5.35190Partial curve; high efficacy-5.01420.80.925776.7855-3.92052.10 0 0 0 0 0 1 0 0 0 0 0 0 0 075.366
Inactive10004-2.6023-5.1436-20.2543-4.2156-18.6587-1.1774-0.484-24.4038-1.4626-19.5587-5.8609-4.7343-6.9928-2.602310-4.16370.90.3781-32.45411.727340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.2572
Inactive10-4.61370.90.4124-15.1446-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.347-0.3142-1.0420.9937-0.4332-5.17271.7846-9.5432-1.6937-2.2733-1.8768-12.2038-8.3511-0.347100041.5347
Inhibitor24.336570.80710004-0.78071.9061-0.7815-4.8851-12.66.6198-2.75363.05454.79781.16051.40111.6918-6.1939-0.78070Partial curve; partial efficacy-4.61371.69240.6988-64.3076.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-29.6108
Inactive10004-0.90493.2372.47662.64980.4207-1.39261.0889-11.66593.0536-1.96911.06293.9096-0.09-0.904910-6.26374.95490.42258.5-0.163240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.6214
Inactive10-4.66371.46410.3698-14.6386-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.0234-8.0187-2.80042.58961.4724-2.46990.0707-3.28221.0981-1.2965-10.7454-0.5498-16.3655-11.023410004-27.7999
Inactive10-6.56424.95490.44474.5-3.852440 0 0 0 0 0 0 0 0 0 0 0 0 0 05.6033-4.33852.27942.7066-14.0436-0.8758-9.51473.77765.08233.93465.49423.25690.88475.603310-6.76424.95490.3433-3.052140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.4886
Inhibitor18.49830.91151000413.22156.882221.7764.66487.65575.4813.49695.24837.72715.712213.43636.7754-1.020413.22150Partial curve; partial efficacy; poor fit-4.73294.95490.5896-30.65330.2582-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.5807
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC363
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197192 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.073 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 237.6 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.75414.95490.42033-4.98140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.9106-3.9228-5.9903-6.0515-1.4717-5.2912-7.602-5.9977-2.42-5.7364-8.2934-0.25662.9408-4.9106QC'd by SigmaAldrichInactive0
Inactive0004-3.3812-1.5662-16.55440.4975-4.09261.5304-12.9724-8.9269-1.91620.6198-11.0605-9.0324-13.3792-3.3812QC'd by SIGMAInactive0
Inactive00041.5277-10.1634-0.00874.0005-6.6661-6.69563.5741-1.09852.27453.2409-13.4326-7.2215-7.42071.5277QC'd by SigmaAldrichInactive0
Inactive0004-1.017-0.1246-23.0301-16.6405-6.1553-10.2548-6.5018-9.7542-2.401-3.4974.2117-8.21190.1193-1.017QC'd by SigmaAldrichInactive0-5.65984.95490.539
Inactive00043.38271.7071.93473.1752-3.8498-3.73072.23732.339-0.9899-3.4194-1.9669-9.73383.77663.3827QC'd by SIGMAInactive0
Inactive0004-0.73285.5587.8092.5786-0.96210.07372.9401-0.38870.14421.36820.83672.63761.7298-0.7328QC'd by SigmaAldrichInactive0
Inactive00042.35882.51021.81950.59232.94893.56280.6572-0.3826-0.85440.17520.73831.72051.81952.3588QC'd by Io-li-tecInactive0
Inactive00041.38781.00940.6532-1.03560.36512.28341.3107-16.37711.71522.1357-0.1164-0.65752.02321.3878QC'd by Io-li-tecInactive0
Inactive00045.46932.7258-1.71972.3804-20.79223.17021.6326-1.2539-13.72260.20822.47040.50210.58075.4693QC'd by SIGMAInactive0-5.85983.06540.6429
Inactive0-4.16644.0450.6851-12.45790.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.54830.2178-0.2309-0.79570.51171.13541.4003-0.03322.55783.2818-3.286-1.4703-0.7627-9.5483QC'd by SIGMAInactive0-4.36641.98870.8468
Inconclusive23.990430.144810Partial curve; partial efficacy; poor fit-4.620.70.747630-0.14482.40 0 0 0 0 0 0 0 0 0 0 0 0 0 022.60371.2906-5.817-1.8818-7.2041.07217.41797.545.08272.19837.159913.888719.365422.6037QC'd by SIGMAInactive0-4.120.50.4
Inactive00042.59482.69211.2072-3.7186-4.66812.76633.94650.38173.5477-0.23396.89892.65815.70112.5948QC'd by AcrosInactive0
Inactive0-4.19134.0450.813213-1.521440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5641-2.86591.25950.2725-1.1592-2.4294-2.1941.7532-2.4893-1.6357-0.1925-1.74781.073610.5641QC'd by SIGMAInactive0
Inactive00047.9141-1.9689-2.253-4.53782.2968-12.15473.36423.88694.99273.8103-8.57025.75174.7237.9141QC'd by SIGMAInactive0
Cytotoxic30.357783.203640Partial curve; high efficacy-4.51771.55790.9633-85.4248-2.2213-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.09710.1445-3.4687-6.33-5.4346-2.1394-5.5181-4.45781.539-0.7887-20.6233-25.9409-48.5781-79.0971QC'd by SIGMACytotoxic60.571591.352241Partial curve; high efficacy-4.21771.3310.9211
Inactive0-4.11374.95490.508311-1.19640 0 0 0 0 0 0 0 0 0 0 0 0 0 07.6371-0.9966-6.4133-1.62961.9829-2.5154-0.6080.0257-0.63170.3616-2.9777-3.0149-0.89117.6371QC'd by SIGMAInactive0
Cytotoxic69.777181.308620Single point of activity-4.15634.95490.9502-84.9425-3.6339-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.79571.365-8.0975-1.71050.6639-11.5921-1.7071-5.2425-4.18560.7387-7.358-7.5217-8.401-69.7957QC'd by SigmaAldrichCytotoxic69.777178.320620Single point of activity-4.15634.95490.9859
Inactive0004-13.1552-4.8346-4.34493.2135-7.58344.6528-8.09981.1002-3.0242.43910.6845-2.3657-3.4277-13.1552QC'd by SigmaAldrichInactive0-6.31074.95490.4218
Inactive0004-22.127-12.1698-7.5453-6.5016-5.9755-2.61933.5381-1.3673-14.7241-1.0064-4.7639-6.1963-2.5303-22.127QC'd by InterchemCytotoxic69.567322.86820Single point of activity-4.15764.95490.8014
Inactive0004-5.0254-5.9486-2.7845-5.6405-2.1794-5.01680.8851-0.4331-4.3384-8.3171-7.9408-6.7025-12.8316-5.0254QC'd by SigmaAldrichInactive0-7.15934.95490.3077
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC907
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-7.31554.95490.55256-10.506740 0 0 0 0 0 0 0 0 0 0 0 0 0 01.801-5.491-7.986-20.8389-13.33246.28051.45194.0156-1.49715.503217.479718.13128.25281.801QC'd by SIGMAInactive0
Inactive0-5.55854.95490.414910-3.634840 0 0 0 0 0 0 0 0 0 0 0 0 0 016.8804-1.78583.6024-6.131-18.86241.55921.63912.0415-8.03311.875915.20442.08323.413816.8804QC'd by SigmaAldrichInactive0
Inactive00048.71311.8866-1.71662.80311.5009-12.00410.7575.6763-5.58230.5326-1.94871.56463.21748.7131QC'd by SIGMAInactive0
Inactive00041.38123.09412.98235.29743.65263.73992.58423.992310.1669.33368.2397-3.59293.03941.3812QC'd by SigmaAldrichInactive0
Inactive0-5.21022.18760.708121.3899-4.687740 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7888-7.3321-7.2161-5.9695-3.47354.0032.56842.7648-12.70273.788413.36314.120524.94961.7888QC'd by ChemServiceInactive0
Inhibitor19.2133337.934344Partial curve; high efficacy-4.71640.50.8478-333.03594.8984-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-252.2999-0.7118-0.9263-5.706-0.121-7.8262-19.3177-30.6174-72.0512-141.5323-123.9442-69.283-223.2304-252.2999QC'd by CytecInhibitor0.541591.790188Complete curve; high efficacy-6.26642.24810.8093
Inactive000416.32936.1544-16.59613.5287-3.494911.62383.5327-5.0571-6.0458-18.6327-4.28816.37352.673916.3293QC'd by SigmaAldrichInactive0
Inactive0-4.55674.95490.4793-23.369-140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-11.59612.49199.058-0.042.1764-12.5203-9.6302-4.47431.7432-2.4338-7.1101-1.5691-22.8075-11.5961QC'd by SIGMAInactive0
Inactive0-4.12184.95490.449526-2.605540 0 0 0 0 0 0 0 0 0 0 0 0 0 020.619-2.119910.8862-0.6531.1832-6.5161-12.30681.6601-2.4009-5.2525-1.0688-1.081-15.921220.619QC'd by SigmaAldrichInactive0
Inhibitor39.277963.752610Partial curve; partial efficacy; poor fit-4.405910.5919-69.8334-6.0808-2.40 0 0 0 0 0 0 1 0 0 0 0 0 0 0-50.3057-6.0808-3.833-13.0728-18.3166-16.1035-3.3344-39.328-14.4105-11.2535-19.6606-3.471-55.4233-50.3057QC'd by SigmaAldrichInactive0
Inactive0-4.30931.3310.825428440 0 0 0 0 0 0 0 0 0 0 0 0 0 021.58514.24835.69328.56476.9910.88430.9534.82571.8614.69056.67246.912515.164121.5851QC'd by SIGMAInactive0-8.80934.95490.3266
Inactive0-7.01910.20.430317.5-12.668140 0 0 0 0 0 0 0 0 0 0 0 0 0 010.0881-3.90832.3807-10.14017.97570.438612.25-0.05663.12176.070511.49712.456319.720110.0881QC'd by SigmaAldrichInactive0
Inactive0-4.86681.98870.55326.9348-3.820740 0 0 0 0 0 0 0 0 0 0 0 0 0 11.3376-7.6928-0.53331.7983-4.65540.58472.4554-8.8369-11.17517.03152.967515.389924.36441.3376QC'd by ChemServiceInactive0
Inactive0-4.13584.95490.546-35.94241.49140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.27790.98835.171-5.248411.3338-0.09311.90132.24583.6879-3.4241-9.6853-6.06656.4942-28.2779QC'd by ChemServiceInactive0-5.88580.30.6749
Activator59.332235.05150Single point of activity-4.22673.990.833838.53.448530 0 0 0 0 0 0 0 0 0 0 0 0 0 033.30954.22966.671610.30334.46525.68211.882812.80621.179613.60763.64714.72757.038733.3095QC'd by SIGMAInactive0
Inactive0004-18.3735-7.17083.2132-14.43274.2935-17.38060.81161.09940.61580.3307-12.4961.5395-1.1314-18.3735QC'd by SIGMAInactive0
Inactive0-4.86151.88510.4207-25.5319-140 0 0 0 0 0 0 0 0 0 0 0 0 0 112.5765-5.8516-15.33963.9162-1.52163.46663.89890.63135.3836-14.6469-0.8588-20.291-21.276612.5765QC'd by SIGMAInactive0-4.86150.30.6157
Activator69.3576284.63330Partial curve; high efficacy-4.15894.95490.9582290.23735.60392.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0239.46977.4741-0.21950.527-1.08286.48486.11090.902420.65386.373815.29646.5792-2.3841239.4697QC'd by SIGMAActivator69.3576259.95740Single point of activity-4.15894.95490.9713
Inactive0-8.81644.95490.4623-26.538540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.1952-9.4853-0.73863.1728-13.46198.36624.0971-0.382711.06927.1292-0.8452-3.79372.19738.1952QC'd by SIGMAInactive0-4.11644.95490.4257
Inactive0-5.16024.95490.810517-5.339140 0 0 0 0 0 0 0 0 0 0 0 0 0 020.0371-5.3775-5.3595-10.6992-6.74984.98782.3993-9.0254-6.8107-9.764111.372511.406218.847720.0371QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HIF170
Protocol: Tox21 Assay Protocol Summary:

HRE-bla ME-180 cells were dispensed at 2,000 cells per well in 6 uL of assay medium containing 0.5% dialyzed FBS into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to each well of the assay plate using a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C and 5% CO2 for 17 hrs. One uL of LiveBLAzerTM B/G FRET substrate (CCF4-AM) (Life Technologies) was added to each well using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA). After 2 hr incubation at room temperature, fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000049734 uM-Replicate_1W530-Activity at 0.0000113459 uM-Replicate_1W530-Activity at 0.0000446985 uM-Replicate_1W530-Activity at 0.0001080938 uM-Replicate_1W530-Activity at 0.0002492385 uM-Replicate_1W530-Activity at 0.0005106135 uM-Replicate_1W530-Activity at 0.00140 uM-Replicate_1W530-Activity at 0.00426 uM-Replicate_1W530-Activity at 0.011 uM-Replicate_1W530-Activity at 0.025 uM-Replicate_1W530-Activity at 0.057 uM-Replicate_1W530-Activity at 0.128 uM-Replicate_1W530-Activity at 0.291 uM-Replicate_1W530-Activity at 0.878 uM-Replicate_1W530-Activity at 2.670 uM-Replicate_1W530-Activity at 7.009 uM-Replicate_1W530-Activity at 15.84 uM-Replicate_1W530-Activity at 35.48 uM-Replicate_1W530-Activity at 76.84 uM-Replicate_1W530-Activity at 198.7 uM-Replicate_1W530-Activity at 725.3 uM-Replicate_1W530-Activity at 1537.0 uM-Replicate_1W530-Activity at 3438.0 uM-Replicate_1W530-Activity at 7687.0 uM-Replicate_1W530-Activity at 17190.0 uM-Replicate_1W530-Activity at 38440.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-3.6553-0.9893-3.5818-1.17650.2463-0.2234-0.9145-0.01270.2733-0.26810.30620.5194-3.3182-3.655310004-0.2957
Inactive100041.82260.0462.81770.4783.4369-1.20180.3150.57551.36561.70740.581-1.5460.3161.822610004-0.7107
Inconclusive21.313826.487710Partial curve; partial efficacy-4.67131.88510.9421270.51232.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.1544-1.23981.60671.0591-0.37590.27121.8173-0.79810.55232.50490.08824.576511.091520.154410004-3.7146
Inactive10-5.27134.95490.37923.5-0.39640 0 0 0 0 0 0 0 0 0 0 0 0 0 11.11-0.22040.39841.729-2.1419-1.0363-2.83-0.8962-0.41591.0879-0.28773.13323.13221.11100040.2226
Inconclusive20.596119.464310Partial curve; partial efficacy; poor fit-4.68620.20.358-21.5626-2.0984-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.687-4.9503-10.9522-8.9046-1.6211-0.082-5.788-7.8292-6.4939-9.6741-10.0897-14.9287-16.3022-10.68710004-0.8617
Inconclusive3.023217.722210Partial curve; partial efficacy; poor fit-5.51950.40.6216-23.6128-5.8906-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 1-12.9702-7.4334-8.7638-12.1242-3.2422-6.6164-6.414-17.1247-10.8286-15.8444-16.4368-20.094-16.7283-12.970210-8.96954.95490.78710.9737.540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.1086
Inactive100041.5223-1.7357-0.7438-3.6994-0.395-0.29530.4241-3.0256-2.7235-1.8125-1.1286-0.6724-2.7321.522310004-0.2476
Inactive10004-12.8642-6.1115-9.8495-9.2614-3.1038-3.26460.1035-13.4348-10.1594-9.5645-9.6545-16.3803-14.6367-12.8642100040.3025
Inactive10004-0.0604-2.1693-3.4849-0.6126-2.4801-0.7035-2.75370.0219-1.0218-2.56510.0598-5.2827-0.7625-0.0604100040.3359
Inactive10004-3.46910.5975-4.6703-1.7651-0.7229-3.1804-0.9474-1.3234-0.6065-3.7492-3.479-2.4871-0.3194-3.4691100042.2474
Inactive10-6.7751.10.3519-3.6702-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9024-0.0717-0.9296-1.0266-2.29810.7439-3.8561-0.582-2.5247-7.2252-4.5423-1.3126-2.0748-0.9024100043.0923
Inactive10004-9.8666-1.1348-6.2751-5.2223-1.99990.0905-0.7847-3.2022-1.5132-2.9373-4.0064-4.484-6.056-9.8666100041.8718
Inactive10004-8.9364-1.2425-5.5217-3.44221.1273-2.75941.619-1.0059-2.884-3.0865-4.52-3.9722-9.247-8.936410-4.40651.66040.93388.5140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1016
Inconclusive10.276517.852710Partial curve; partial efficacy; poor fit-4.98820.60.445-20.2075-2.3548-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.1898-3.0172-8.3806-7.0506-3.6035-1.3277-0.2956-8.0513-1.2813-9.1424-7.6654-15.1729-14.3238-7.189810004-1.0635
Inactive10-5.74990.60.6027-15.0694-4.122240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.8447-4.9088-8.1722-1.7685-3.24-3.1309-4.6399-11.5479-7.3956-9.2891-12.3039-14.1602-14.2245-11.8447100043.318
Inconclusive4.395417.188910Complete curve; partial efficacy; poor fit-5.3570.80.5163-25.9259-8.737-1.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.6982-6.7445-16.6319-7.1908-5.879-5.5985-3.9475-15.8575-10.3684-14.7455-20.4174-24.9382-21.2805-18.6982100044.3064
Inactive10004-13.1388-3.3075-12.7272-9.0493-9.8786-7.1457-2.8049-12.1577-10.9471-13.3333-12.2337-20.0526-10.5047-13.1388100041.101
Inactive10-4.89190.90.709-13.2479-140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.6909-2.1257-2.7415-1.45671.4230.53370.4156-2.3538-1.045-5.073-2.362-8.7847-11.0399-3.6909100041.1903
Inactive10-4.64144.95490.57843.5-1.853540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.62650.4697-2.8233-2.4-4.4612-1.6658-0.927-1.6545-0.2803-2.145-0.0407-1.23645.26151.6265100041.1602
Inactive10-4.56044.95490.54737-1.629440 0 0 0 0 0 0 0 0 0 0 0 0 0 10.1793-2.1537-0.4036-2.87041-5.5245-0.3415-3.2205-1.4272-0.2922-5.2662-2.17246.53540.1793100040.9083
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Penicillium chrysogenum
External ID: CHEMBL960283
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 1992
Volume: 55
Issue: 5
First Page: 620
Last Page: 625
DOI: 10.1021/np50083a010

Target ChEMBL ID: CHEMBL612847
ChEMBL Target Name: Penicillium chrysogenum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=200ug.mL-1
MIC=800ug.mL-1
MIC=200ug.mL-1
MIC>800ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC=400ug.mL-1
MIC=800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
MIC>800ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: H2AX721
Protocol: Tox21 Assay Protocol Summary:

The CHO-K1 cells suspended in culture medium containing 10% FBS were dispensed at 1000 cells/ 3 ul/well in 1536-well white wall/solid bottom plates (Greiner Bio-One North America, NC) using a Multidrop Combi (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37C overnight, 23 nl of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station (Wako, San Diego, CA) into each well resulting in a final DMSO concentration of 0.76%. After 3hr incubation at 37C, 3 uL/well CellTiter-Glo luminescent cell viability reagent (Promega Corporation, Madison, WI) was added using a Flying Reagent Dispenser (FRD) (Aurora Discovery, CA). After incubation at room temperature for 30 min, the luminescence intensity was read using a ViewLux plate reader (PerkinElmer, Waltham, MA).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000100212 uM-Replicate_1Activity at 0.0000229890 uM-Replicate_1Activity at 0.0000909942 uM-Replicate_1Activity at 0.0002163761 uM-Replicate_1Activity at 0.0005012188 uM-Replicate_1Activity at 0.00103 uM-Replicate_1Activity at 0.00284 uM-Replicate_1Activity at 0.00871 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.051 uM-Replicate_1Activity at 0.114 uM-Replicate_1Activity at 0.255 uM-Replicate_1Activity at 0.582 uM-Replicate_1Activity at 1.781 uM-Replicate_1Activity at 5.430 uM-Replicate_1Activity at 14.00 uM-Replicate_1Activity at 31.63 uM-Replicate_1Activity at 70.87 uM-Replicate_1Activity at 154.2 uM-Replicate_1Activity at 401.1 uM-Replicate_1Activity at 1455.9 uM-Replicate_1Activity at 3087.0 uM-Replicate_1Activity at 6902.0 uM-Replicate_1Activity at 15430.0 uM-Replicate_1Activity at 34510.0 uM-Replicate_1Activity at 77170.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Cytotoxic0.195816.579320Single point of activity-6.70814.95490.6356-17.0793-0.5-30 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.0378-0.07892.0497-4.0824-1.52491.28180.3598-15.06615.2629-1.5796-2.6816-2.6592-1.481-0.0378QC'd by ACCInactive0-7.95813.990.358
Inactive043.2303-5.2610.91491.7511-0.9651.5180.41441.2813-4.8181-8.566-3.01530.40231.03723.2303QC'd by ACCInactive0
Inactive042.6334-0.4566-0.24132.79170.73373.49855.35830.74840.4867-0.23133.50311.23690.75822.6334QC'd by ACCInactive0
Inactive045.14512.97753.87223.1624-2.6383-1.7577-2.117110.59053.2733-0.5395-0.05624.28030.11225.1451QC'd by ACCInactive0
Inactive04-3.6748-2.4298-0.6747-3.1974-7.4289-2.8005-2.60937.3711-4.7494-6.4707-2.9423-3.1292-6.3414-3.6748QC'd by RTIInactive0
Inactive0-4.106310.6242-13.9734-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.97781.6144-1.4479-3.95650.076-5.6314-1.40311.244-2.3399-2.0506-1.5683-5.5983-6.2459-9.9778QC'd by RTIInactive0
Inactive0-4.21014.0950.3917-6.2749-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.0624-0.57771.191-3.8357-1.4631-1.6187-3.87122.41012.2699-1.78380.574-1.198-4.7749-6.0624QC'd by RTIInactive0
Inactive04-6.2845-6.4479-2.6819-0.9491-5.5321-3.63081.9302-1.1485-4.5456-3.1284-3.4839-2.2626-3.9496-6.2845QC'd by RTIInactive0
Inactive0-3.450.90.4298-13.7287-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.7739-0.5915-0.5427-2.26743.129-4.3159-3.0773-0.4174-0.3897-1.8236-7.365-0.639-3.1035-9.7739QC'd by RTIInactive0
Cytotoxic45.904415.988820Complete curve; partial efficacy-4.33814.95490.8599-16.9888-1-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.3573-1.6405-0.1185-4.391-3.34390.26140.1829-2.90071.2236-2.46020.516-3.2239-17.4906-15.3573QC'd by RTICytotoxic57.790219.151620Complete curve; partial efficacy-4.23814.95490.6765
Inactive0-4.41173.990.8619-10.9831-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.9372-2.0267-0.9393-1.66530.09420.2489-2.1983-0.5132-2.20040.1676-1.8927-6.1292-13.3192-8.9372QC'd by RTIInactive0
Cytotoxic94.101494.77642Partial curve; high efficacy-4.02643.1320.9876-95.3228-0.5468-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.79-2.37250.2589-3.28970.7307-1.0945-0.847-1.70852.7324-3.2271-0.0239-0.2899-30.464-79.79QC'd by RTICytotoxic105.583587.355742Partial curve; high efficacy-3.97644.44950.9851
Cytotoxic127.898275.716942Partial curve; high efficacy-3.89311.210.7142-78.6996-2.9828-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.6209-1.1995-2.582-0.801-0.7702-5.2133-6.0E-4-3.9281-0.099-7.38-6.3771-34.7211-7.476-59.6209QC'd by RTICytotoxic28.6328123.74920Single point of activity-4.54312.40640.8306
Inactive0-3.97460.60.6973-12.5364-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.78030.9175-2.09581.2549-1.23831.43091.0801-2.1662-2.6553-2.8983-4.02-2.9099-5.1369-8.7803QC'd by RTICytotoxic118.957316.037320Partial curve; partial efficacy; poor fit-3.92460.90.7158
Cytotoxic91.940426.641821Partial curve; partial efficacy-4.03653.06540.9323-27.1418-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.86820.53250.7878-0.5764-0.2246-2.89571.3672-1.4009-2.8906-2.8280.19151.1536-10.4047-23.8682QC'd by RTICytotoxic73.030925.702821Partial curve; partial efficacy-4.13653.51170.9553
Cytotoxic90.445521.118220Partial curve; partial efficacy; poor fit-4.04361.88510.6485-24.6182-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.1818-3.5991-0.9613-8.8603-5.261-1.9156-2.4825-12.1501-2.5401-0.8207-5.1003-2.8595-12.2432-22.1818QC'd by RTICytotoxic80.609621.332220Partial curve; partial efficacy-4.09361.88510.8349
Inactive04-7.93740.9285-2.2382-1.0931-2.5705-6.96450.1194-2.3351-0.81211.284-0.7640.8797-5.3686-7.9374QC'd by RTIInactive0
Inactive04-4.5331-1.6685-2.39040.58240.2176-2.6217-3.9140.73360.0474-3.1743-0.0069-2.8617-8.6171-4.5331QC'd by RTIInactive0-5.47880.30.7769
Inactive04-2.3056-1.4405-2.2094-1.8577-1.6091-0.00590.1594-1.4245-0.9456-2.1159-0.5644-1.3464-4.2856-2.3056QC'd by RTIInactive0
Inactive0-4.29720.70.5972-7.6054-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4403-1.6095-0.4996-0.9438-1.2942-0.94991.0478-1.6707-1.3686-1.0617-4.9494-1.064-5.5045-5.4403QC'd by RTIInactive0-3.89720.40.4901
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: HIF512
Protocol: Tox21 Assay Protocol Summary:

HRE-bla ME-180 cells were dispensed at 2,000 cells per well in 6 uL of assay medium containing 0.5% dialyzed FBS into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to each well of the assay plate using a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C and 5% CO2 for 17 hrs. One uL of LiveBLAzerTM B/G FRET substrate (CCF4-AM) (Life Technologies) was added to each well using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). After 2 hr incubation at room temperature, fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). For cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using an FRD. After 30 min incubation at room temperature, the luminescence intensity was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152025 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.60324.0950.64957-2.700740 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1758-4.2575-0.8849-0.5073-1.8009-7.6673-2.86610.1917-0.6812-1.2122-5.0182-1.00364.92727.1758QC'd by TCIInactive0-7.15323.990.4691
Inactive0-6.75750.20.6588-24.3563-0.170840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.4636-4.8496-8.5344-10.1028-14.3441-10.343-14.2235-11.4306-14.1952-18.1832-11.9322-14.9262-14.9623-24.4636QC'd by SIGMAInactive0-7.55751.62660.7962
Inactive00040.5977-0.7538-0.8916-2.8779-3.0565-5.0177-5.8497-6.2902-0.3941-5.3169-0.7029-2.38370.72570.5977QC'd by ChemServiceCytotoxic17.561183.395741Partial curve; high efficacy-4.75541.62590.9741
Inactive0-4.45440.60.6816-30.3523-2.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.3769-4.6229-0.5495-1.2895-1.1193-12.13114.0955-0.9288-5.7619-9.7965-12.511-12.2886-12.1517-22.3769QC'd by CrescentInactive0
Inactive0-4.95441.88510.9636-30.318-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.03140.50570.3708-1.2987-0.0781-5.2462-1.11230.80840.2592-2.641-8.1573-19.3031-30.265-26.0314QC'd by SIGMACytotoxic22.159172.288720Single point of activity-4.65444.95490.9483
Inactive0-4.20384.50450.676616-2.965540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.8414-4.0057-0.109-1.78660.0869-3.6625-9.5546-4.9082-0.61-2.786-4.3728-2.7969-1.836410.8414QC'd by SigmaAldrichInactive0
Inactive0-4.94951.82650.9274-33.9853-61.540140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-38.7609-60.7983-57.7742-60.0884-64.8103-59.1302-65.3149-63.658-60.1957-60.6665-54.3555-43.9534-33.3211-38.7609QC'd by SigmaAldrichInactive0
Inactive0004-4.1397-2.9877-1.83381.1979-10.7008-1.7544-1.1569-2.2875-3.3128-2.3864-5.2743-0.26821.7528-4.1397QC'd by SigmaAldrichInactive0-4.70584.95490.7058
Inactive0004-5.8179-5.051-0.68060.5857-0.6234-4.5622-3.8615-1.3297-3.5351-8.9704-10.877-7.88430.1856-5.8179QC'd by SigmaAldrichInactive0-4.3742.33320.6555
Inactive0004-9.9825-1.6216-0.6635-5.2568-0.7064-0.73850.4011-0.9831-5.9428-1.712-6.379-8.825-0.6433-9.9825QC'd by SigmaAldrichInactive0
Inactive0004-8.24010.7083-12.582-1.555-1.5841-0.99266.0648-10.9222-9.8317-1.6314-19.7387-9.04398.5004-8.2401QC'd by SIGMAInactive0
Inactive0-4.91454.95490.540912.51.574440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.3217-0.14334.82590.34674.15480.21845.10389.20720.90632.8403-5.354612.657214.18879.3217QC'd by SensientCytotoxic10.850938.753621Partial curve; partial efficacy-4.96451.88510.985
Cytotoxic38.168351.019720Partial curve; partial efficacy-4.41832.40640.7543-52.141-1.1213-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.531-0.30450.3523-3.7746-0.08513.3224-0.4139-0.226-9.87290.41153.59950.7027-26.9055-42.531QC'd by SIGMAInactive0-4.26834.95490.9124
Inactive00046.73872.7960.1416.00960.266.04240.29035.3783-10.3279-1.3301-1.98070.55341.0526.7387QC'd by SIGMAInactive0-6.55683.06540.7495
Inactive0-4.41582.72020.499213.5-0.204840 0 0 0 0 0 0 0 0 0 0 0 0 0 011.4311-0.1318-0.1192-2.1669-2.4026-0.47710.5652-2.26862.29990.1723-0.219-0.32865.908511.4311QC'd by SIGMAInactive0-5.06583.92950.3811
Inactive0004-1.37410.25470.5081.221-1.343-2.0309-0.68440.0949-1.60341.0326-4.1250.2241-1.2696-1.3741QC'd by SIGMAInactive0
Inactive0-4.39741.10.4549-0.393740 0 0 0 0 0 0 0 0 0 0 0 0 0 07.3303-2.31921.414-4.9114-0.3542.6407-0.15680.74260.3671-0.05451.08881.48262.55997.3303QC'd by SIGMAInactive0
Inactive00044.0189-2.49471.2236-0.56551.1538-2.0889-2.06983.13650.5040.18410.37760.58323.45024.0189QC'd by SIGMAInactive0
Inactive00044.07422.03523.4602-0.6876-0.18963.1220.24180.43210.3714-0.80881.43034.6376-1.94074.0742QC'd by FLUKAInactive0-6.37634.95490.551
Inactive0-5.44954.95490.41323.5-1.067440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8554-0.2996-0.2381-3.8228-0.2096-3.80041.63590.3602-2.58850.23935.5561.53523.7894-2.8554QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: H2AX604
Protocol: Tox21 Assay Protocol Summary:

The CHO-K1 cells suspended in culture medium containing 10% FBS were dispensed at 1000 cells/ 3 ul/well in 1536-well white wall/solid bottom plates (Greiner Bio-One North America, NC) using a Multidrop Combi (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37C overnight, 23 nl of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station (Wako, San Diego, CA) into each well resulting in a final DMSO concentration of 0.76%. After 3hr incubation at 37C, 1 uL/well Supplemented Lysis buffer (diluted 100 fold blocking reagent in lysis buffer) (HTRF Phospho-H2A.X (S139) Assay kit from Cisbio US Inc., Bedford, MA) was added using a Flying Reagent Dispenser (FRD) (Aurora Discovery, CA). After 10sec spin at 1000 rpm in a plate centrifuge, the assay plates were incubated at room temperature for 30 min. Then followed by the addition of 1 uL/well detection buffer (containing a mixture of two antibodies, one labeled with cryptate, Anti pH2AX (S139)-K and another labeled with d2, Anti H2AX-d2) using FRD. After incubation at room temperature for 24 hr, the time resolved fluorescence at excitation 320 nm and emissions at 665 nm and 620 nm was measured using an Envision plate reader (PerkinElmer, Waltham, MA).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W620-Activity_Score-Replicate_1W620-Curve_Description-Replicate_1W620-Fit_LogAC50-Replicate_1W620-Fit_HillSlope-Replicate_1W620-Fit_R2-Replicate_1W620-Fit_InfiniteActivity-Replicate_1W620-Fit_ZeroActivity-Replicate_1W620-Fit_CurveClass-Replicate_1W620-Excluded_Points-Replicate_1W620-Max_Response-Replicate_1W620-Activity at 0.0000100212 uM-Replicate_1W620-Activity at 0.0000229890 uM-Replicate_1W620-Activity at 0.0000909942 uM-Replicate_1W620-Activity at 0.0002163770 uM-Replicate_1W620-Activity at 0.0005012188 uM-Replicate_1W620-Activity at 0.00103 uM-Replicate_1W620-Activity at 0.00284 uM-Replicate_1W620-Activity at 0.00871 uM-Replicate_1W620-Activity at 0.022 uM-Replicate_1W620-Activity at 0.051 uM-Replicate_1W620-Activity at 0.114 uM-Replicate_1W620-Activity at 0.255 uM-Replicate_1W620-Activity at 0.582 uM-Replicate_1W620-Activity at 1.781 uM-Replicate_1W620-Activity at 5.453 uM-Replicate_1W620-Activity at 14.00 uM-Replicate_1W620-Activity at 31.63 uM-Replicate_1W620-Activity at 70.87 uM-Replicate_1W620-Activity at 154.2 uM-Replicate_1W620-Activity at 401.1 uM-Replicate_1W620-Activity at 1455.9 uM-Replicate_1W620-Activity at 3087.0 uM-Replicate_1W620-Activity at 6902.0 uM-Replicate_1W620-Activity at 15430.0 uM-Replicate_1W620-Activity at 34510.0 uM-Replicate_1W620-Activity at 77170.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-6.95810.40.4668-1.3477-7.973440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4019-5.4309-8.3112-7.4244-5.4208-0.6969-6.5272-2.9697-6.5206-4.8941-0.5496-0.9734-3.7779-2.4019104-0.1994
Inactive104-0.8865-1.2427-0.10122.7689-1.2051-8.0331-5.6601-3.2832-1.2739-1.30180.9228-3.4270.4966-0.8865104-1.2268
Fluorescent55.196533.330110Single point of activity-4.25811.92820.698632-1.330130 0 0 0 0 0 0 0 0 0 0 0 0 0 023.3727-5.2171-8.1918-2.84561.0030.09960-2.16164.727-5.48962.26846.26634.656323.372710-8.20812.24810.3141-1.0212240 0 0 0 0 0 0 0 0 0 0 0 0 0 00.5571
Inactive104-3.0709-9.96180.7982-5.2192-0.5692-7.4363-1.8669-1.2646-6.986367.4176-2.9179-3.7281-0.9825-3.07091042.655
Inactive10-7.72294.95490.339-1.7182240 0 0 0 0 0 0 0 0 0 0 0 0 0 02.61022.22290.57310.318-2.5399-0.2987-1.5265-3.9318-3.3363-3.134-1.9675-1.7341.76152.6102104-0.1089
Inactive1042.7579-1.57941.15321.1346-2.0421.2942-1.69611.24990.9043-2.1472-3.28342.9771-3.35412.7579104-2.7282
Inactive1040.3103-6.58781.75191.80410.9792-3.4345-4.0663-4.2039-4.2626-3.1864-0.08561.4332-0.7270.31031043.6137
Inactive104-1.1081-6.8305-4.7329-5.9552-0.0549-6.737-0.7996-9.2941-6.0746-0.5427-2.1729-2.8132-2.3094-1.10811040.5597
Inactive10-8.350.90.4324-1-10.594340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4474-5.3962-0.0826-3.1558-1.3558-0.4378-3.4408-2.8376-1.0188-0.97340.8621-1.9522-1.96323.4474104-4.44
Inactive104-0.7343-8.0348-3.0411-0.1542-1.28041.7882-1.1388-9.1341-4.2303-2.967-1.0623-1.1713-0.1655-0.734310-3.78814.95490.5013-5.32120.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.7677
Inactive10-6.71171.62660.3188-0.5-2.820840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.2805-0.0514-4.2641-2.6332-4.8507-0.5406-1.432-1.41880.7593-1.54291.0907-1.0329-2.0198-1.28051040.481
Inactive104-11.2334-7.1625-2.2867-5.4475-3.7778-2.3395-7.3034-0.3656-3.4483-9.3653-5.5476-10.4351-11.3637-11.23341044.3704
Inactive104-2.86241.0493-2.5635-1.9363-0.226-2.2897-2.38710.5577-1.1759-2.1626-3.16020.4219-0.9845-2.86241042.242
Inactive104-1.6903-1.0786-2.1965-1.3298-0.06540.0541-3.2054-1.5765-5.5016-5.03210.1563-0.4334-3.7092-1.69031040.1926
Inactive1041.1876-1.5971-4.1158-1.27110.0502-3.6804-4.3519-3.952-1.267-0.0663-0.569-7.508-2.8771.18761041.4021
Inactive1040.24620.6799-1.6187-2.99681.55590.7002-0.4152-0.23540.933-1.4204-2.95051.2689-2.16810.2462104-1.6194
Inactive104-2.21620.1318-2.90266.8735-2.20941.0407-1.7947-2.3121-4.59980.82981.171-5.44561.1958-2.2162104-2.9548
Inactive1040.65650.6163-1.1595-0.8031-2.2181.3415-4.049-3.3028-3.4787-2.39650.1898-0.73210.38440.6565104-1.8324
Inactive1041.1241-8.5235-3.20041.8669-4.8174-0.1069-0.6147-2.4142-1.0633-2.48770.1282-1.2367-1.58931.12411040.1357
Inactive10-6.94720.80.4048-0.5-3.161940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.1519-2.2985-3.492-1.744-3.1132-2.3395-0.2181-1.8917-0.8137-1.06751.9967-2.542-1.2665-3.15191040.9974
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV463
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive041.72950.52943.18025.8576-13.2261-2.70962.32773.08360.66810.8553-2.5716-8.80020.93361.7295QC'd by ACC0
Inactive0-5.67134.95490.4567-9.5364-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.4931-0.3132-9.0031-1.37862.9342-0.62741.4692.0742-1.31910.8343-7.1697-14.1560.3555-9.4931QC'd by ACC0
Activator16.9301626.649349Partial curve; high efficacy-4.77131.3310.9768639.241312.5922.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0495.5359-1.9437-0.28722.264960.37582.736523.80731.9884.584813.458684.9728135.6152319.9522495.5359QC'd by ACC0
Inactive0-9.17134.95490.3243-4.16692440 0 0 0 0 0 0 0 0 0 0 0 0 0 14.49519.1079-2.92392.9475-1.1252-3.1158-19.7224-18.7137-5.55731.73914.3407-0.5794-17.21864.495QC'd by ACC0
Inactive04-1.4338-5.1613-13.4065-11.08192.2196-9.8309-7.493519.6175-11.68-6.5454-3.0084-1.3924-0.0854-1.4338QC'd by RTI0
Inactive04-0.06572.7267-14.8963-0.59042.5835-4.97911.54130.4423-5.1268-14.4299-8.05080.6303-10.6572-0.0657QC'd by RTI0
Inactive04-2.2898-1.05085.84332.72411.9566-1.76592.149-5.0045-8.03727.387518.2729-3.414514.9169-2.2898QC'd by RTI0
Inactive04-2.66921.559137.22210.9092.2412.8103-4.2918-5.3244-6.3058-0.6797-2.999917.4880.0577-2.6692QC'd by RTI0
Inactive04-7.8369-7.29973.8528-6.08521.198756.327-0.252-6.6076-2.0431-2.85932.836660.13680.7004-7.8369QC'd by RTI0
Inactive0-7.90134.44950.42791-11.008940 0 0 0 0 0 0 0 0 0 0 0 0 0 01.1506-12.4702-10.9207-3.67122.24471.34810.8136-4.3714.0377-2.89721.43973.8914-3.2241.1506QC'd by RTI0
Inactive041.11810.1768-5.3052-0.94990.09024.06750.0846-0.6164-0.42438.7148-3.13170.6008-2.02271.1181QC'd by RTI0
Inactive0-7.78970.80.3897-2-17.425340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-11.4437-14.023-15.1485-15.88081.8136-13.5013-8.13622.80881.5308-16.02122.2517-5.7850.4858-11.4437QC'd by RTI0
Inactive04-10.42311.28533.5569-3.1220.92258.3539-5.9784-6.6058-9.2911-3.1787-3.4870.71291.4318-10.4231QC'd by RTI0
Inactive0-7.73824.95490.30320.011512.211240 0 0 0 0 0 0 0 0 0 0 0 0 0 11.52880.950616.703814.1576-2.5052-1.4079-7.1617-2.59110.2899-1.46337.03017.09990.33931.5288QC'd by RTI0
Inactive0-8.54990.80.6938-2.94661840 0 1 0 0 0 0 0 0 0 0 0 0 0 0-4.125112.009133.24450.68950.67250.2088-2.7945-1.4329-3.4616-5.9923-1.3187-2.4253-0.3401-4.1251QC'd by RTI0
Inactive04-0.8939-2.9136-1.9824-0.2399-1.3445-0.37655.8516-2.01614.2702-3.190856.3924-0.94610.5242-0.8939QC'd by RTI0
Inactive04-8.7412-6.5753-17.70663.7172-10.82516.8532-5.6494-1.0518-7.7844-4.0289-6.4104-4.9608-14.2816-8.7412QC'd by RTI0
Inactive04-8.43490.6625-12.86764.0735-4.892734.2082-7.0634-7.0056-4.6588-0.7159-10.6746-6.22913.8264-8.4349QC'd by RTI0
Inactive04-8.0905-8.9909-7.30310.6324-11.7986-17.7946-11.0081-10.6951-13.728-15.7973-13.7019-0.8883-7.3389-8.0905QC'd by RTI0
Inactive047.7339-3.1519-12.65715.9451-3.8215-9.616611.4708-10.59340.5021-4.2503-7.881-10.49670.61947.7339QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV208
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive042.8556-6.3304-0.7647-8.8733-1.31120.8858-0.7954-2.57631.03362.1512-9.58190.21270.5852.8556QC'd by SIGMA0
Inactive04-7.8426-4.3078-16.60170.242-13.2719-11.6752-0.79161.95570.8861-16.7872-2.3074-10.3741-2.8885-7.8426QC'd by SIGMA0
Inactive0-4.21014.95490.4665320.65440 0 0 0 0 0 0 0 0 0 0 0 0 0 025.3647-1.024-9.455-4.84037.0107-0.83190.7153-0.51971.3173-2.122121.3-1.94980.638125.3647QC'd by SIGMA0
Activator10.9622354.094588Complete curve; high efficacy-4.96011.88510.9871350.4672-3.62731.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0308.1942-1.3985-5.089-0.241-8.8635-0.459-5.64280.57321.391323.285681.7578248.9758341.586308.1942QC'd by SIGMA0
Inactive0-4.21034.95490.404514-0.05940 0 0 0 0 0 0 0 0 0 0 0 0 0 011.96942.92772.7682-4.33181.2545-0.3862.9265-3.3749-0.10960.69872.85880.883-6.299211.9694QC'd by SIGMA0
Inactive04-13.0353-2.27130.1463-3.5651-12.8612-3.9456-7.20940.7903-1.74652.1902-4.8911-11.17319.074-13.0353QC'd by Enamine0
Inactive0-4.66014.95490.572422-4.384840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.1612.5163-10.0126-10.1585-10.3418-5.59460.93372.7621-4.0144-12.8206-6.8537-0.243720.2317-3.161QC'd by Acros0
Inactive04-7.4276-3.9949-3.4557-6.7725-8.6378-3.7241-4.4626-9.5948-6.0438-0.4032-7.51030.5018-6.0984-7.4276QC'd by SIGMA0
Activator54.941165.51310Single point of activity-4.26014.95490.9754156.7033-8.809730 0 0 0 0 0 1 0 0 0 0 1 0 0 0131.9051-3.0176-7.8198-5.984-12.7666-12.3564212.7294-11.8023-3.2899-12.078168.6093-7.3461-9.2414131.9051QC'd by LightBiologicals0
Activator21.8724188.631741Partial curve; high efficacy-4.66012.63840.9884181.566-7.06562.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0189.1313-6.8974-9.5309-15.2558-4.7097-9.1661-13.1889-0.3751-4.4697-4.7565-3.896451.8043130.9924189.1313QC'd by SIGMA0
Inactive0-4.46011.210.5164-15.5464-141 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.955414.77360.1105-0.3273-0.6686-1.19261.6937-0.1163-2.6784-9.52550.8128-1.5346-10.5306-12.9554QC'd by SIGMA0
Inactive0-4.21014.95490.465-22.3147-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.92891.2242-10.46842.60172.96771.2054-1.31262.3634-4.18770.0322-1.4713-0.911-0.8096-16.9289QC'd by Enamine0
Inactive044.45532.40422.23260.41450.24591.92160.4022-0.87521.5279-1.3064-0.98321.2208-0.59624.4553QC'd by LightBiologicals0
Inactive040.31653.88260.36471.64325.15721.7629-7.38692.44130.0071-1.3988-7.01262.4097-0.29750.3165QC'd by SIGMA0
Inactive04-1.8527-6.04173.3136-21.7204-0.80272.34064.71844.32133.25283.59745.3302-0.15211.3023-1.8527QC'd by SIGMA0
Activator3.8895232.94451Partial curve; high efficacy-5.41011.47870.9923230.9277-2.01642.10 0 0 0 0 0 0 0 0 0 0 0 0 1 162.38620.4013-5.072-0.61550.58821.3374-1.29933.258221.944396.8738157.7951204.7231124.904862.3862QC'd by SIGMA0
Inactive04-3.47891.4151-13.25430.1998-1.77564.16140.810614.65013.76140.68722.5933-0.70390.494-3.4789QC'd by ChemService0
Inactive0-5.36014.95490.3211-5.731040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.73460.55414.9704-5.8731-0.6018-6.8821-1.45694.11891.88980.1337-7.25430.1379-8.5259-6.7346QC'd by SIGMA0
Inactive040.0083-0.6469-9.92481.92781.2911-0.062-5.6651-3.0476-0.16126.3388-7.89081.4553-6.56660.0083QC'd by SIGMA0
Inactive0-7.61014.95490.3777-1.7299640 0 0 0 0 0 0 0 1 0 0 0 0 0 01.83795.69061.496510.08612.0512-2.1055-0.94551.516621.5335-14.3582-0.32220.0976-0.37391.8379QC'd by ChemService0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV378
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-4.9327-8.7446-7.1163-2.5925-13.0435-1.7843-2.484-3.6729-7.613-0.8889-4.8878-7.5645-0.6005-4.9327QC'd by SIGMA0
Inactive04-16.415-8.5001-2.0629-19.3599-6.5839-1.4707-9.8236-3.5022-4.2079-3.24190.1219-5.8248-9.6459-16.415QC'd by SIGMA0
Inactive04-10.7413-7.39220-0.2838-0.5653-4.5221-3.0423-6.7941-2.6028-14.553-0.3935-3.6205-12.0068-10.7413QC'd by SIGMA0
Inactive043.2663.16150.08866.5708-1.32983.14050.67442.5665-6.09993.2181.004916.1034.23573.266QC'd by SIGMA0
Cytotoxic54.799939.068320Single point of activity-4.26124.95490.6959-38.67160.3967-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.39179.59144.3283-0.759-4.06415.535-4.0123-9.3196-1.0468-1.3955-5.42130.0991-1.6536-32.3917QC'd by SIGMA0
Inactive04-5.73092.4973-8.6586-4.0186-3.069512.231313.719.8546-5.47310.4059-3.83138.4712.9818-5.7309QC'd by SIGMA0
Inactive0-7.05671.96730.5185-1.2735.540 0 0 0 0 0 0 0 0 0 0 0 0 0 110.3592.8275.80910.02684.8573.60620.9278-1.1672-0.7265-0.7966-6.4775-0.77652.138810.359QC'd by SIGMA0
Inactive0-8.01492.33320.3168-1.860140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.70960.2868-5.71687.12927.41961.630516.89211.03154.11626.683716.156210.6194.529213.7096QC'd by SIGMA0
Inactive0418.46045.7588.027-2.207411.8158-1.23930.152411.417911.842511.9427.8774-0.79384.7718.4604QC'd by SIGMA0
Inactive04-3.1832-3.0169-21.80232.0915-0.17060.85444.67233.83911.6775-3.1957-4.5826-1.7625.6197-3.1832QC'd by SIGMA0
Inactive047.06459.82295.06560.6911-2.4601-2.9394-0.43582.99575.00434.57664.344910.4285.47957.0645QC'd by SIGMA0
Inactive042.87990.629-10.63982.0031-0.51151.142-1.08143.68224.59776.9657-0.74484.399614.49732.8799QC'd by SIGMA0
Inactive041.50152.66799.95341.34317.349517.04560.9676-3.3756-0.89150.99653.49348.230615.41721.5015QC'd by SIGMA0
Inactive04-4.07418.0515-9.6192-9.13193.341-15.15631.344611.16750.4706-5.54756.1638-8.9391.0036-4.0741QC'd by SIGMA0
Inactive0419.28391.7535-1.83222.628214.76662.45912.84031.7826-3.637912.539-0.274713.7515-2.088619.2839QC'd by SIGMA0
Inactive04-6.837-4.13767.35992.9047-1.07680.16948.3141.13760.9196-7.8482-6.9238-0.58641.4242-6.837QC'd by SIGMA0
Inactive0-5.70660.70.566221.939140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.1135-1.102106.448313.25958.79225.6758-3.3848.396913.63420.653922.032513.87680.1135QC'd by SIGMA0
Inactive049.5114.849813.2582.0698-2.30842.241823.650616.2267-0.179922.16161.8408-0.3677-0.42029.511QC'd by SIGMA0
Inactive0-4.24844.95490.446625-0.037740 0 0 0 0 0 0 0 0 0 0 0 0 0 020.76270.901-2.66373.17736.35525.97582.4992-2.72392.61-0.87970.7471-17.94812.574120.7627QC'd by SIGMA0
Inactive04-10.2166-8.0741-1.4322-10.2813-2.02430.8873-4.2479-4.2814-3.429-4.25980.2946-0.0902-2.3971-10.2166QC'd by TCI0